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Your health is our concern
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volunteer-led health and dementia groups throughout Norway. Our goal is to 
combat cardiovascular disease and dementia by funding research, preventative 
measures, providing information and influencing government and politicians. 
Our work is funded by voluntary donations. 
A love of what you do is one of the highest forms of success. 
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Introduction
Heart failure, diastolic dysfunction and myocardial stiffness 
The pumping action of the heart generates the pressure needed to transport blood 
throughout the circulation, allowing exchange of nutrients for metabolic waste products. It 
is no surprise that dysfunction of this vital organ has serious consequences for physical 
performance and well-being. Regardless the reason, severe dysfunction of the heart results 
in heart failure, a condition defined by failure of the heart to pump blood at a rate 
commensurate with the requirements of the metabolizing tissues.2 Despite advanced 
medical treatment, the 5-year survival rate is merely 40-60%3,4 and although prevalence of 
heart failure is high, it is projected to further increase with the growing elderly population.  
Heart failure is a result of dysfunction during systole and/or diastole. Whereas 
systolic dysfunction, involving compromised contraction of the heart, has been heavily 
studied, diastolic dysfunction has only recently become recognised as a major cause of 
heart failure5,6,7,8 and has thus gained increasing amount of attention in the cardiovascular 
research community. Defined by abnormal relaxation and/or decreased compliance of the 
ventricles,9 diastolic dysfunction results in impaired filling of the heart in diastole. In 
healthy individuals, the major risk factor for diastolic dysfunction is age. However, any 
condition that leads to stiffening of the ventricles can result in diastolic dysfunction, e.g. 
pressure overload as in hypertensive and aortic stenosis patients. Myocardial stiffness is 
largely determined by the structure and composition of the extracellular matrix (ECM), and 
diastolic dysfunction is often a result of myocardial fibrosis. There is currently no effective 
medical treatment for myocardial fibrosis, reflecting the need for a better understanding of 
its molecular basis. This comprises the background for the overall motivation of the work 
summarised in this thesis. 
All cells in all tissues are constantly affected by the mechanical properties of the 
extracellular environment, while these same cells are generating forces that regulate the 
extracellular environment. In this way, equilibrium is achieved thereby maintaining tissue 
structure and function and enabling physiological adaption to signals that result in normal 
growth and development. In the heart, the extracellular environment is mainly regulated by 
cardiac fibroblasts. These are major producers and organisers of ECM and are highly 
plastic cells that adjust their phenotype and function to meet the challenges of the 
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mechanical load that is constantly inflicted upon the heart. When the balance between 
mechanical stress and cellular response is disturbed, pathological remodelling may occur 
compromising cardiac function and ultimately causing heart failure. In this thesis, we have 
investigated the role of the transmembrane proteoglycan syndecan-4 in transducing 
mechanical stress into cellular changes in cardiac fibroblast function and phenotype, and 
studied the consequence of these changes on ECM remodelling and myocardial stiffness.
Cardiac fibroblasts and myofibroblasts
Cardiac fibroblasts comprise more than 50% of the total cell population in the human 
heart10,11 and up to 30% of the total cells in the murine heart.12 These plastic cells are 
responsible for a balanced production and turnover of ECM. In response to pressure 
overload of the heart, cardiac fibroblasts proliferate, boost ECM synthesis and develop 
contractile forces that act on the freshly produced ECM thereby remodelling tissue 
structure to meet the increased mechanical burden.13 Hence, they are smooth muscle cell-
like in terms of expressing markers defining smooth muscle cells such as smooth muscle Į-
actin (SMA)14 and SM22, but at the same time retain typical fibroblast features such as the 
ability to produce large amounts of ECM. Cells with this phenotype are therefore referred 
to as myofibroblasts.15
Of particular relevance for myocardial stiffness is the high expression of fibrillar 
collagen I that is maturated into large collagen fibers through extensive cross-linking 
mediated by the enzyme lysyl oxidase, providing tensile strength to the ECM. In the 
normal adaptive response, myofibroblasts will undergo apoptosis16 as ECM tension is 
restored and again takes over the mechanical load. However in situations where 
mechanical load continues to be elevated such as in patients with chronic hypertension, 
persistent myofibroblast activity and development of myocardial fibrosis is observed.17
Also of interest and in agreement with these results, a recent report suggests that cardiac 
myofibroblasts may dedifferentiate back into fibroblasts when mechanical tension is 
decreased or in the presence of a transforming growth factor ȕ(7*)ȕ)-receptor-I kinase 
blocker.18 Whether one or both of these interventions were needed to accomplish 
dedifferentiation, depended on the proliferative status of the myofibroblasts indicating the 
presence of multiple degrees of differentiation. It will be important to determine whether
these findings also apply to myofibroblasts in vivo. 
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The fibroblast-myofibroblast phenotypes do not reflect one single cell type but 
rather a continuum of functional statuses, and to date no markers exclusively expressed in 
myofibroblast have been identified. Myofibroblasts are most commonly defined by the 
high expression of collagen I and de novo expression of SMA and the extradomain A (ED-
A) splice variant of fibronectin.19 Also, platelet-GHULYHGJURZWKIDFWRUUHFHSWRUȕ
3'*)5ȕKDVrecently arisen as a promising myofibroblast marker in several tissues.20,21
The heterogeneity of myofibroblasts may also reflect their many potential cellular origins. 
This issue has been debated over several years and has been deluded by the observation 
that many cell types will adopt a myofibroblastic phenotype in vitro when stimulated with 
TGFȕ. The traditional view is that myofibroblasts in the heart derive from resident cardiac 
fibroblasts, but endothelial cells,22 bone-marrow-derived circulating progenitor cells23,24
and pericytes25 surrounding blood vessels may also contribute. 
TGFȕLVDSRWHQWLQGXFHURIcardiac myofibroblast differentiation.26,27 A
requirement for TGFȕ-induced myofibroblast differentiation is the expression of ED-A19
and mechanical stress.28 This may indicate that TGFȕLVVHFRQGDU\WRPHchanical stress-
induced changes, emphasizing the importance of studying mechanosensing of cardiac 
fibroblasts. Although it is well-established that mechanical stress induces differentiation of 
cardiac fibroblasts into myofibroblasts,29 the underlying mechanisms are largely unknown. 
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Figure 1. The mechanical loop of cardiac myofibroblast differentiation.
1) Quiescent fibroblasts residing in the cardiac tissue have low extracellular matrix (ECM) producing 
activity and regulate the basic turnover of ECM. 2) In response to mechanical stress, such as in the 
pressure-overloaded heart, cardiac fibroblasts start producing ECM and forming actin stress fibers and 
focal adhesions (FA) that apply traction forces on the ECM thereby increasing matrix stiffness. 3) This 
further promotes myofibroblast differentiation increasing FA size and initiating expression of ED-A splice 
variant of fibronectin (FN). Transforming growth factor ȕ(TGFȕ) is produced or released from the 
ECM20,30 and works in a paracrine and autocrine fashLRQWRLQGXFHH[SUHVVLRQRIĮ-smooth muscle actin 
(SMA) and increase ECM production. Again, all these properties promote ECM stiffening. 4) FAs will keep 
growing in size and become “super mature”, and SMA molecules will incorporate into functional SMA 
stress fibers with high contraction force, hence marking the completion of the myofibroblast phenotype.
Myofibroblasts persist as long as mechanical stress continues to be elevated, producing more and more 
ECM in a viscous cycle until cardiac fibrosis finally compromises cardiac function to a degree where 
transition to heart failure is unavoidable. 5) Alternatively, myofibroblasts may ultimately undergo apoptosis 
when the ECM maturates and takes over the mechanical load. Whether myofibroblasts may 
dedifferentiate back into quiescent resting cardiac fibroblast when mechanical stress in alleviated in vivo,
is not entirely clear. Modified with permission from Hinz, 2007.31
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Syndecan-4 in cardiac fibroblasts: one protein, multiple roles 
Syndecans are a family of evolutionary ancient transmembrane heperan sulfate
proteoglycans which consists of four family members (syndecan-1-4) in mammals.32 The 
core proteins of syndecans have a cytoplasmic part, a transmembrane region and an 
extracellular domain (ectodomain). The intracellular cytoplasmic part consists of two 
constant regions (C1 and C2) that are conserved among the syndecan family, and a 
variable (V) region that is unique to each syndecan.33 Multiple interaction partners 
including cytoskeletal proteins, adaptor proteins and signalling molecules have been 
identified as being essential for syndecan structure and function.34,32 In conjunction with 
the cytoplasmic domain of syndecan-4, the transmembrane domain is responsible for 
syndecan-4 dimerization35,36 by forming strong twisted clamp dimers as shown by NMR 
structural studies.37 These dimers may occur during synthesis, implying that the dimeric 
state of syndecans is the native one. The ectodomains of syndecan-1,38 -2 and -439 have 
been found to promote integrin-mediated adhesion of mesenchymal cells although the 
mode of interaction is not known. The extracellular domains of syndecans display little 
homology but have in common that they are all substituted with glycosaminoglycan 
(GAG) chains, mainly heparan sulfate (HS). These GAG chains may vary in length, 
charge, sugar composition and degree of sulfation and may therefore also display a wide 
array of functions. HS can interact with numerous and different types of ligands including 
growth factors,40 chemokines41 and matricellular proteins,42,43 and thereby possibly act as 
co-receptors for other cell surface receptors.44,45,46 HS GAG chains also interact with 
extracellular structural proteins such as collagen I47 and fibronectin48 and are highly 
hygroscopic due to their negative charge.  
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Figure 2. Summary of syndecan 
structure and interactions. 
All four syndecans share this basic 
structure containing an extracellular 
domain (ectodomain), transmembrane 
domain, and a cytoplasmic domain 
consisting of constant regions and a 
variable region specific for each 
syndecan. Heparan sulfate GAG chains 
are attached to the ectodomain. The 
domains have different functions and 
interaction partners enabling syndecans to 
hold multiple roles in cellular function and 
phenotype.
Since the first description of syndecans in 198849 the importance of syndecans in 
health and disease has been a riddle. Although profound effects of syndecan-4 activation or 
inhibition on cell behavior are observed, mice lacking syndecan-1, -3 or -4 have only mild 
defects upon initial observation, suggesting some degree of redundancy among syndecans 
or HS-proteoglycans in general. On the other hand, syndecan-specific effects are clear 
when syndecan knockout mice are subjected to injury or disease.50,51,52 The first hint that 
syndecans played a role in connective tissue remodelling and fibroblast function was the 
detection of syndecan-1 expression in granulation tissue around growing capillaries.53 Both 
syndecan-1 and syndecan-4 knockout mice have since confirmed this initial observation,
having delayed wound healing in skin50 and adverse matrix remodelling after myocardial 
infarction increasing susceptibility to cardiac rupture.54,55 The myocardial ECM defects of 
syndecan-4 knockout (syndecan-4-/-) mice were largely attributed impaired fibroblast 
responses; however the exact mechanisms were not determined.54
Mechanical stress sensor
The existence of mechanosensing molecules in the plasma membrane of cardiac cells has 
long been a focus of attention. Such a mechanosensor is likely attached to the ECM as well 
as to the cytoskeleton, forming a physical link between extra- and intracellular structures. 
Transmembrane proteins with such properties are found in focal adhesions (FAs). FAs are 
points in the cell membrane that constitute the binding sites to the ECM and are likely to 
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be involved in mechanosensing and mechanotransduction.56,57 FAs consist of cell binding 
receptors such as integrins, cytoskeletal proteins, and signalling molecules, many of which 
are known to interact with syndecan-4. These include syntenin,58 CASK59, synectin,60 focal 
adhesion kinase (FAK)61 and protein kinase C (PKC).62,36 During myofibroblast 
differentiation FA size and strength increase, developing into “super mature” FAs63 which 
may affect downstream signalling molecules.
Located in FAs, and being attached both extracellularly to fibronectin64 and 
LQWUDFHOOXODUO\WRWKHF\WRVNHOHWRQWKURXJKĮ-actinin,65,66 syndecan-4 is an attractive 
candidate for a mechanosensor.67 In a previous study by our group,51 syndecan-4 was 
found to play such a role in cardiomyocytes inducing concentric hypertrophic remodelling
of the left ventricle in response to pressure overload. The underlying mechanism for this 
effect involved activation of the transcription factor nuclear factor of activated T cells 
(NFAT) which is a well-known inducer of hypertrophy in the pressure-overloaded 
heart.68,69 NFAT is heavily phosphorylated in its inactive state and changes conformation 
following dephosphorylation thereby revealing a nuclear localisation signal causing
nuclear translocation and transcription of target genes.70,71 Although NFAT has been 
extensively studied in cardiomyocytes, the role of NFAT in cardiac fibroblasts is highly 
elusive. There are four calcium-regulated NFAT isoforms (NFATc1-4), all expressed in 
cardiac fibroblasts at the mRNA level, NFATc3 having the highest expression, followed by 
NFATc1, NFATc4 and NFATc2.  
Dephosphorylation of NFAT is performed by the Ca2+-sensitive phosphatase 
calcineurin.72 The intracellular part of syndecan-4 was found to bind to the autoinhibitory 
domain of calcineurin when syndecan-4 was dephosphorylated at serine179, and 
experiments assessing NFAT activation suggested that this binding activated calcineurin
and subsequently NFAT. Indeed, activation of this syndecan-4/calcineurin/NFAT 
signalling pathway was present in the pressure-overloaded hypertrophic heart and in 
mechanically stressed cardiomyocytes,51 but its presence in cardiac fibroblasts was not 
examined. In Paper 1 we examined a possible mechanosensing role for syndecan-
4/calcineurin/NFAT in cardiac fibroblasts, inducing myofibroblast differentiation and 
ECM production. Since these are important for regulating mechanical properties of the 
heart, we examined the consequence of syndecan-4 deletion on myocardial stiffness in 
Paper 2.
18
 
Organiser of cytoskeleton and extracellular matrix assembly 
Syndecan-4 plays a central role in cytoskeletal organization and focal adhesion assembly 
and turnover,44,73 having profound effects on migration,74 adhesion75 and cell spreading.64
The mechanism for this involves PKCĮ activation76 in response to a conformational 
change of syndecan-4 that occurs upon binding of phosphatidylinositol 4,5-bisphosphate 
(PIP2) to the cytoplasmic domain of syndecan-4. This also leads to clustering of syndecan-
4, coordinated by PDZ domain-containing scaffold proteins, and interaction of syndecan-4 
ZLWKWKHF\WRVNHOHWRQYLDĮ-actinin.77 3.&ĮDFWLYDWHVthe small GTPase RhoA73 and its 
kinases leading to focal adhesion assembly and stress fiber formation through their 
phosphorylation of myosin phosphatase and myosin II.78 Fibroblasts lacking syndecan-4 
have smaller focal adhesions and defect cytoskeleton substantiating the role of syndecan-4 
in organizing these structures.  
Many ECM structural proteins are assembled into fibers at the cell surface after 
secretion where cell surface receptors bind and initiate fibrillogenesis. Although focal 
adhesions are thought to be important matrix assembly points, the exact role of syndecan-4 
in matrix assembly is not known. The heparin-binding domains of fibronectin are required 
for fibrillognesis79 and studies manipulating syndecan-2 structure or expression reveal 
impaired assembly of laminin and fibronectin at the cell surface.80,81 Syndecan-4 may also 
interact with collagen I through its GAG chains,47 although the effect of this interaction of 
collagen fibrillogenesis is unknown. In Paper 2 we extend our findings on the regulatory 
role of syndecan-4 cytoplasmic domain, to explore the role of the extracellular domain of 
syndecan-4 in regulating collagen fibril assembly and cross-linking.
Expression and shedding 
Cardiac syndecan-4 expression has been shown to be increased in the hypertrophic 
myocardium of mice after myocardial infarction82 and in human aortic stenosis.51 Reports 
from other cell types indicate a role for mechanical stress,83 tumor necrosis factor Į
(TNFĮ)84,85,86 and interleukin 1ȕ (IL-1ȕ)85 in regulating syndecan-4 expression. TNFĮ and 
IL-1ȕ are cytokines associated with the innate immune system which is activated upon 
tissue injury and exposure to pathogens.87 71)Į and IL-ȕ were initially discovered in 
cells of the immune system88,89 but have since proven to be present in a wide variety of cell 
types, including cardiac cells.90,91,92,93 Importantly, 71)Į and IL-ȕ are rapidly (within 2h) 
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upregulated after inducing left ventricular pressure overload by aortic banding (AB;
unpublished results). 
 The ectodomain of syndecan-4 can be shed by proteolytic cleavage. This is a highly 
regulated process involving the direct action of “sheddase” enzymes.94 In the heart, 
syndecan-4 shedding is elevated in response to myocardial injury and disease as indicated 
by increased plasma levels after myocardial infarction in humans95 and in serum from 
patients with chronic heart failure.96 Syndecan-4 shedding may play several roles in the 
cardiac response to mechanical stress such as decrease mechanosensing by syndecan-4 and
disrupt cellular attachment to ECM thus abrogating down-stream signalling of syndecan-4 
and promoting migration, respectively. In addition, the shed ectodomain may itself act as a 
soluble effector or antagonist,94 or create a chemotactic gradient for leukocyte infiltration 
of the myocardium.97
The question whether syndecan-4 shedding is good or bad for cardiac function 
remains to be answered. In studies of myocardial infarction, overexpression of the 
extracellular shed part of syndecan-4 increased mortality,54 whereas overexpression of full-
length syndecan-4, showed reduced mortality and improvement of cardiac function.98 The 
role of shedding in the pressure-overloaded heart is not known. However, syndecan-4 
shedding was induced by stretch of vascular smooth muscle cells,99 indicating regulation in 
response to mechanical stress. In Paper 3 we investigate the regulation of syndecan-4 
expression and shedding, and examine its effect on inflammation and focal adhesion 
assembly.  
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Figure 3. Multiple proposed roles for syndecan-4.
The location of syndecan-4 in focal adhesions (FAs) suggests that it plays a role in sensing and 
transducing mechanical stress. B) Heparan sulfate chains of syndecan-4 interact with extracellular matrix 
(ECM) molecules promoting assembly into higher order ECM structures. C) Syndecan-4 acts as a co-
receptor enhancing signalling by soluble factors such as growth factors. D) Enzymatic shedding of 
syndecan-4 ectodomain may enable the creation of a chemotactic gradient by binding and thereby 
increasing the concentration of chemokines in the ECM. E) The deprived attachment to ECM after 
shedding abrogates intracellular signalling and may enhance cell migration.
21
 
Aims of the thesis
The overall aim of this thesis was to investigate the role of syndecan-4 in cardiac fibroblast 
function and phenotype, ECM remodelling and myocardial stiffening of the pressure-
overloaded heart.
The specific aims of the separate studies were: 
1. To study whether syndecan-4 signals via calcineurin/NFAT to regulate 
myofibroblast differentiation and ECM production in response to mechanical stress
2. To examine the role of syndecan-4 in regulating myocardial stiffness and explore if 
syndecan-4 may be important for collagen cross-linking 
3. To investigate the signals and mechanisms that induce cardiac syndecan-4 
expression and shedding 
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Methodological considerations
To study the role of syndecan-4 in mechanical stress-induced changes we use model 
systems of mechanical stress in vivo and in vitro, as well as “gain and loss of function” 
approaches where we manipulate the expression of syndecan-4 in mice and in fibroblast 
cultures. This enables us to study the consequence of lacking syndecan-4 on the 
mechanical stress response of the heart and study molecular mechanisms by use of cell 
biology techniques such as syndecan-4 overexpression.  
 
Models of mechanical stress
Animal model of left ventricular pressure overload
Mechanical stress is elevated in patients with pressure overload of the left ventricle, i.e. 
hypertension or aortic stenosis. To mimic aortic stenosis, AB of the ascending aorta was
performed. As controls, sham-operated animals underwent an identical operation but 
without tightening the suture around the aorta. To ensure successful AB, flow velocity 
across the aortic stenosis was determined with echocardiography 24h after AB. Animals 
with an aortic flow velocity > 4 m/s after AB were included in the study. After 24h or 7 
days, echocardiography was performed as previously described,51,100 obtaining left 
ventricular dimensions and parameters of cardiac function. Animals were sacrificed 24h, 3 
days or 7 days after AB, and lung and left ventricular weight were obtained as an 
indication of congestive heart failure and hypertrophy, respectively. Left ventricular tissue 
was snap frozen or fixed for further analysis. Although using mouse models to study 
human disease have obvious limitations such as body size, heart rhythm, mode of left 
ventricular pressure overload onset (immediate pressure overload in AB mouse model v.s. 
gradual increase in humans) and time frame for development of disease (days and weeks in 
AB mouse model v.s. several years in humans), the AB mouse model of left ventricular 
pressure overload is considered a valid model of concentric hypertrophy of the heart.101
Mechanical stress in vitro
To study mechanisms involved in mechanotransduction and cardiac myofibroblast 
differentiation in vitro, we isolated primary cardiac fibroblasts from left ventricles of 
neonatal and adult mice.51 The mechanical tension of the culturing conditions will itself 
induce myofibroblast differentiation of primary cardiac fibroblasts.28 In addition, 
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fibronectin enhances attachment of cardiac fibroblasts and drives myofibroblast 
differentiation.102 Although this makes studies on cardiac fibroblasts challenging, we took 
advantage of these two properties and studied the process of myofibroblast differentiation 
by examining cardiac fibroblasts at different time points after culturing them on 
fibronectin. Although SMA protein amount reflects myofibroblast phenotype, it is not 
always coherent with fiber formation. Thus, myofibroblast differentiation was determined 
by the appearance of SMA stress fibers by immunocytochemistry. The limitations of this 
myofibroblast differentiation model are mainly associated with the type of mechanical 
stress induced by the culturing conditions which is unlike the cyclic mechanical stretch that 
cardiac fibroblasts experience in vivo. Also, the ECM in vivo is composed of a wide variety 
of proteins and not just fibronectin as studied here. That said, highly controlled culturing 
conditions are needed to get reliable and consistent results in vitro, since the cardiac 
fibroblast exhibit high plasticity. The myofibroblast differentiation model used here was
simple, consistent and, in our opinion, appropriate for the purpose.  
Although immortalised cell lines such as the fibrosarcoma human cell line HT1080 
are cultured for long periods of time and for several passages, they have fewer features of
myofibroblasts than primary cardiac fibroblasts in culture. To induce myofibroblast 
differentiation of this cell line, we subjected them to 10% cyclic (1 Hz) mechanical stress 
by using the FlexCell tension system, thereby mimicking the mechanical stress present in 
the heart.103 Since FlexCell stretch membranes are unsuitable for immunocytochemistry, 
myofibroblast differentiation was determined by upregulation of the early myofibroblast 
marker ED-A FN.19
Gain and loss of function studies
Genetically modified mice
Genetically modified mouse models have enabled huge progress in understanding the 
importance of specific proteins in vivo, and are widely used in basic research. We have 
used syndecan-4-/- mice to study the role of syndecan-4 in the pressure-overloaded heart. 
To study the regulation of NFAT transcriptional activity, we utilised NFAT-luciferase 
reporter mice69 that express the luciferase enzyme when NFAT is activated. Luciferase 
enzymatic activity can then be measured as luminescence when luciferin (the substrate of 
luciferase) is added to the protein lysate of homogenised tissue or cell cultures. To study 
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the role of syndecan-4 in NFAT activation, syndecan-4-/--NFAT-luciferase reporter mice 
(generated in our laboratory) were used.  
The syndecan-4-/- mouse is a complete knockout, meaning that syndecan-4 protein 
is lacking in all cells of the body which may complicate interpretation of in vivo data 
regarding cell-specific functions of syndecan-4.50 Also, syndecan-4 protein will be absent 
from the time of birth. Thus, compensatory mechanisms may have emerged or 
developmental processes may have been disturbed, thereby affecting the phenotype of the 
adult mouse. Regardless, “loss of function” mouse models comprise powerful tools in 
medical research.  
Manipulating gene expression in vitro
The use of primary cells in culture enables discrimination of responses in cardiac 
fibroblasts and cardiomyocytes, which are both present in tissue homogenates harvested 
directly from the left ventricle. In the studies included in this thesis, primary neonatal 
cardiomyocytes and cardiac fibroblasts from neonatal and adult syndecan-4-/- mice have 
been isolated to examine changes in cellular responses when syndecan-4 is lacking. 
Although cardiac cell types are in constant interaction within the heart, cell-specific in 
vitro studies provide valuable insight into cell function, phenotype and molecular 
signalling mechanisms.  
“Loss of function” studies in the primary cells from syndecan-4-/- mice can be
complimented by “gain of function” experiments. Plasmids containing full-length 
syndecan-4 cDNA under the control of a strong promoter were transfected into fibroblasts 
and thereby caused syndecan-4 overexpression. Since primary cell lines are difficult to 
transfect, we used a fibroblast cell line for this purpose. Often such “gain of function” 
studies strengthen findings from “loss of function” experiments showing opposite effects,
but sometimes results are conflicting and interpretation becomes a challenge. The biology 
of living cells harbors a plethora of regulatory mechanisms that fine tune cell behavior and 
activity. Thus, the amount of protein does not always translate into effect. Transfection 
with plasmids also enables introduction of genes encoding modified proteins, e.g. carrying 
fluorescent tags such as enhanced green fluorescent protein (EGFP). In Paper 1, we utilised
EGFP-NFAT fusion proteins which allowed us to determine cellular localization of EGFP-
NFATc1-4 and thereby examine which NFAT isoforms were activated (determined by 
nuclear translocation) in response to mechanical stress. 
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Myocardial stiffness 
The combined passive mechanical properties of the myocardium such as viscosity and 
elasticity constitute the myocardial stiffness. Viscous stress reflects the stretch velocity 
sensitive component of the muscle, and is highly determined by the amount of water 
present in the tissue. On the other hand, passive tension is dependent on the amplitude of 
stretch and reflects the elastic properties of the muscle. In the heart, passive tension is 
largely determined by the cytoskeletal spring-like protein of cardiomyocytes called titin, 
and the composition and structure of ECM. In response to changes in mechanical load such 
as in the pressure-overloaded heart, modifications in all these properties may take place 
and thereby increase myocardial stiffness.
 In Paper 2 we determined the passive tension of myocardial tissue strips isolated 
from the left ventricular wall. The strips, about 2 mm in length and 0.5 mm in width, were 
dissected parallel to muscle fiber bundle orientation. To eliminate the active component of 
myocardial stiffness, skinning of the preparations was performed using 0.5% triton in 
calcium free solution. To eliminate the contribution of titin to passive tension, salt 
extraction of actin and myosin filaments was performed by treatment with 0.6 M KCl for 
20 min and 1 M KI for 20 min.104
Passive tension was measured by mounting the strips between two stainless steel 
clips attached to a micromotor and force transducer. It is essential for accuracy to 
standardise the initial length from where stretching is started (L0). Slack length was used as 
L0 in this study and strips were stretched in equal steps to 30% of L0. Ideally L0 is set by 
measuring sarcomere length of the cardiomyocytes in the preparation. By using laser 
diffraction105,106 we were able to verify in three muscle strips that the applied range of 
stretch corresponded to a sarcomere length of 1.8 – 2.3 μm. Passive tension was obtained 
by dividing force with the cross-sectional area at the thinnest point of the strip. Disruption 
of sarcomere structure was verified by subsequent examination of muscle strips with
electron microscopy. Viscous stress was determined as peak force upon stretching minus 
steady-state force, divided by cross-sectional area.
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Collagen expression and maturation 
Fibrous collagens are macromolecules that have a high content of hydroxyproline. Hence, 
a standard procedure for quantifying total collagen is to measure hydroxyproline content 
with high-performance liquid chromatography (HPLC). However, not only the amount of 
protein but also the degree of collagen cross-linking is important for tensile strength of the 
collagen matrix. 
Collagen cross-linking can be assessed both quantitatively and qualitatively by 
staining with picrosirius red. Picrosirius red stains all collagen a deep red colour and can be 
visualised in tissue sections of the heart using standard light microscopy. Also, this linear 
molecule binds parallel to the long axes of collagen fibers, thereby enhancing birefringence 
of collagen that can be visualised when the sample is illuminated with polarised light.107
To quantify collagen cross-linking, we stained thick (20 μm) tissue sections of the left 
ventricle with two different dyes: Picrosirius red to stain total collagen and fast green to 
stain total non-collagen protein. These dyes are readily extracted from the stained tissue 
and the amount of collagen relative to total protein can be calculated based on absorbance 
DWȜ(for picrosirius) DQGȜ (for fast green). To assess the amount of soluble collagen 
(not cross-linked), tissue sections were incubated with pepsin overnight. The amount of 
pepsin-solubilised collagen was determined by a colorimetric assay that is also based on 
picrosirius red staining. Finally, cross-linked collagen could be determined by subtracting 
soluble collagen from total collagen. This protocol for quantitating cross-linked collagen 
was adapted from the Diez group in Pamplona108 after a research visit by members of our 
group.  
To study the role of the extracellular domain of syndecan-4 in collagen fiber 
assembly in vitro, recombinant syndecan-4 consisting of the extracellular part of syndecan-
4 fused with the Fc region of human IgG1 was mixed with collagen I in a test tube. The 
effect of adding recombinant human lysyl oxidase homolog 2 was also examined. 
Turbidity of the solution served as a measure of collagen fibrillogenesis and samples were 
further examined with electron microscopy after negative staining with 2% aqueous uranyl.
Although this is a highly artificial and non-physiological method, it does shed light on the 
ability of the ectodomain of syndecan-4 to facilitate collagen I fiber formation and how it 
may play a role in matrix assembly in vivo.  
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Molecular biology techniques
Additional molecular biology techniques used in this thesis include: quantitative real-time 
PCR, LOX activity assay, migration scratch assay, ELISA for syndecan-4 in plasma, 
adenoviral transduction of primary cardiac fibroblasts, western blot, proximity ligation 
assay and immunocytochemistry. A challenge with several of these methods is the 
dependency on antibodies, where specificity will always be a question. To increase the 
soundness of our antibody-based results we have complemented with other methods, used 
antibodies with verified specificity (such as pNFATc4/NFATc4109), and used blocking 
peptides (for the proximity ligation assay) and multiple negative controls when applicable. 
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Summary of Results 
Paper 1 
In this study we demonstrated the importance of syndecan-4 in differentiation of cardiac 
fibroblasts into myofibroblasts. Mechanically-stressed cardiac fibroblasts from  
syndecan-4-/- mice had impaired SMA production and fiber formation in vitro, and markers 
of myofibroblasts were reduced in vivo following AB. Furthermore, mRNA of central 
ECM genes such as collagen I, III and fibronectin were upregulated in a syndecan-4-
dependent manner in response to pressure overload. We also showed that NFAT is 
activated in cardiac fibroblasts in response to mechanical stress. This activation was 
dependent on syndecan-4 and calcineurin, demonstrated by reduced NFAT activity in 
cardiac fibroblasts from syndecan-4-/- mice and in the presence of the calcineurin inhibitor 
cyclosporine, respectively. By utilizing EGFP-NFAT fusion proteins, NFATc4 was found 
to be the NFAT isoform that was activated by mechanical stress. Accordingly, over-
expression of NFATc4 upregulated collagen III and myocardin-related transcription factor 
A (MRTF-A), the latter being a transcriptional regulator of SMA. Syndecan-4 and 
calcineurin were localised closely together suggesting interaction between the two 
molecules. This possible interaction may be promoted when syndecan-4 is 
dephosphorylated at serine179, which has previously been shown to be critical for 
interaction between calcineurin and syndecan-4 cytoplasmic domain in response to 
mechanical stress.51 We concluded from this study that syndecan-4 engages the 
calcineurin/NFAT pathway to induce differentiation of cardiac fibroblasts into 
myofibroblasts and ECM production in response to mechanical stress.  
Paper 2 
In this study we found that passive tension increased in response to AB (7 days AB), but 
the response was blunted in syndecan-4-/- mice. Disruption of titin anchoring by salt 
extraction of actin and myosin filaments revealed that the effect of syndecan-4 on passive 
tension was due to ECM remodelling. Expression and activity of the cross-linking enzyme 
lysyl oxidase (LOX) increased with mechanical stress and was lower in left ventricles and 
cardiac fibroblasts from syndecan-4-/- mice, which exhibited less collagen cross-linking 
after 7 days AB. Expression of osteopontin (OPN), a matricellular protein able to induce 
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LOX protein in cardiac fibroblasts, was upregulated in hearts after AB, mechanically-
stressed fibroblasts and fibroblasts overexpressing syndecan-4, calcineurin or NFAT, but 
downregulated in fibroblasts lacking syndecan-4 or after NFAT inhibition. Interestingly, 
the extracellular domain of syndecan-4 facilitated LOX-mediated collagen cross-linking.
Hence, syndecan-4 appears to exert a dual role in collagen cross-linking, one involving its 
cytosolic domain and NFAT signalling leading to collagen, OPN and LOX induction in 
cardiac fibroblasts; the other involving the extracellular domain promoting LOX-
dependent cross-linking. 
Paper 3 
In vivo, syndecan-4 mRNA expression was upregulated by 24h and 1 week AB-induced 
pressure overload. In vitro, TNFĮ, IL-1ȕ, and lipopolysaccharide (LPS), induced syndecan-
4 mRNA in both cardiac myocytes and fibroblasts. Bioinformatical and mutational 
analyses in human embryonic kidney 293 (HEK293) cells identified a functional site for 
the pro-inflammatory transcription factor nuclear factor kappa B (NF-țB) in the syndecan-
4 promoter and indeed, NF-țB regulated syndecan-4 mRNA in cardiac cells. Interestingly, 
TNFĮ, IL-1ȕ and LPS also induced NF-țB-dependent shedding of the syndecan-4 
ectodomain from cardiac cells. To examine the specific cleavage site of syndecan-4, 
overexpression experiments of syndecan-4 with mutated enzyme-interacting domains were 
performed and suggested enzymes dependent on binding to heparan sulfate to regulate 
shedding. LPS-induced shedding reduced FA size of cardiac fibroblasts, suggesting that 
inflammation-induced shedding affects cardiac fibroblast function. After AB, a time-
dependent cardiac recruitment of T lymphocytes was observed by measuring CD3, CD4 
and CD8 mRNA, which was reduced in syndecan-4-/- hearts. Finally, syndecan-4 mRNA 
and shedding were upregulated in failing human hearts. Conclusively, our data suggest that 
syndecan-4 plays an important role in the immune response of the heart to increased 
pressure, influencing cardiac remodelling and failure progression. 
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Discussion 
Mechanosensing by syndecan-4 in cardiac fibroblasts induces myofibroblast 
differentiation
Syndecan-4 is located in focal adhesions, sites known to be important for 
mechanotransduction in adherent cells.110 Here, transmembrane proteins enable bi-
directional signalling between the cytoskeleton and ECM. In response to pressure overload 
of the left ventricle, syndecan-4 is rapidly upregulated as demonstrated in Paper 1 and 3. 
Similar to vascular smooth muscle cells,83 mechanical stress induced syndecan-4 
expression in cardiomyocytes, but the in vitro mechanical stress applied for these 
experiments (10% stretch, 1 Hz, 24h) had no effect on syndecan-4 expression in cardiac 
fibroblasts. The proinflammatory cytokines IL-1ȕ and TNFĮ caused upregulation 
syndecan-4 in both cardiomyocytes and cardiac fibroblasts through activation of NF-Ƹ%.
Thus, upregulation of syndecan-4 in cardiac fibroblasts seems to be triggered by autocrine 
and paracrine signalling induced by pressure overload more than mechanical stress per se.
Left ventricular syndecan-4 expression peaks at 6h post AB (unpublished data) and 
declines back to initial levels 3 weeks after AB. In light of the rapid upregulation in the 
pressure-overloaded heart, it seemed likely that syndecan-4 might play a pivotal role in the 
immediate response to mechanical stress and possibly trigger other signalling pathways 
that take over at later time points. Based on previous findings by others67 and us51,82 and 
the work presented in Paper 1 and 2, we propose syndecan-4 to be a transducer of 
mechanical stress in cardiac fibroblasts that is active in initial stages of the pressure 
overload response.  
Bellin and collegues were the first to show a direct role for syndecan-4 in 
mechanotransduction.67 By using antibodies directed toward the ectodomain of syndecan-4 
they were able to specifically study extracellular binding properties of syndecan-4. 
Application of mechanical stress exclusively to syndecan-4 caused activation of specific 
mechanosensitive signalling pathways in NIH 3T3 fibroblasts.111 This 
mechanotransduction was dependent on intact actin filaments. In Paper 1 we found 
impaired SMA fiber formation and others have reported reduced RhoA activity in cardiac 
fibroblasts from syndecan-4-/- mice,54 suggesting altered cytoskeletal dynamics in cells 
lacking syndecan-4, thus contributing to the blunted fibroblast response to mechanical 
stress. 
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In Paper 1 and 2 we demonstrated impaired cardiac myofibroblast differentiation in 
response to mechanical stress in vitro (SMA fiber formation) and in vivo
(immunohistochemistry for SMA and PDGFRȕ) when syndecan-4 was lacking. Results 
from Paper 1 indicated that the mechanism for syndecan-4–dependent myofibroblast 
differentiation involved dephosphorylation of serine179 in the cytoplasmic domain of 
syndecan-4 thereby possibly functioning as a mechanical stress-sensitive switch for
activation of the calcineurin/NFAT signalling pathway. Overexpression of NFATc4 
enhanced the expression of collagen III, MRTF-A (Paper 1) and OPN (Paper 2). Apart 
from a few studies showing that NFAT can regulate collagen I,112,113 SMA114 and OPN115
expression in other tissues, syndecan-4/calcineurin/NFAT regulation of myofibroblast 
differentiation and ECM production was a novel finding in this study.  
Although little is known regarding the role of NFAT in cardiac fibroblasts, studies 
manipulating cardiac calcineurin and NFAT activity in vivo have indicated a role for 
NFAT in cardiac fibrosis,116,117,118,119 and blocking NFAT in vivo and in vitro reduced
fibrosis and expression of matricellular proteins, respectively, in response to mechanical 
stress.120 Furthermore, recent publications have examined a potential role for NFAT in 
regulating cardiac fibroblast phenotype. In primary cardiac fibroblasts isolated from the 
left atria of dogs subjected to atrial fibrillation, NFAT activity was increased leading to
proliferation of cardiac fibroblasts and upregulation of ECM gene expression. The 
mechanism was attributed upregulation of transient receptor potential canonical (TRPC) 
channel 3, a cation channel permissive to calcium.121 TRPC channels are known to activate
calcineurin/NFAT signalling in the heart122 and in a study by the Molkentin group123 mice 
lacking TRPC6 had impaired myofibroblast differentiation and cardiac wound healing after 
injury due to reduced calcineurin/NFAT signalling. In contrast, NFAT activity in response 
to endothelin-1 (ET-1)-induced upregulation of TRPC6 was found to suppress 
myofibroblast differentiation in rat neonatal cardiac fibroblasts124 despite ET-1 being a 
profibrotic ligand. In these studies, TRPC6 was upregulated by TGFȕ and ET-1, 
respectively, suggesting that calcineurin/NFAT signalling is secondary to these mediators.
In Paper 1 we suggest a direct activation of calcineurin/NFAT via syndecan-4 by 
mechanical stress, that is independent of 7*)ȕand ET-1 signalling.  
Results from Paper 1 suggested that syndecan-4 could regulate MRTF-A expression 
by activating NFAT. Being an essential cofactor for the transcription factor serum response 
factor (SRF), MRTF-A is well-established from studies in vascular smooth muscle cells to 
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be central for SMA expression by binding to CArG boxes in the promoter region of the 
SMA gene (ACTA2),125,126 and was also recently found to be necessary for myofibroblast 
differentiation.127 The collagen 1a2 promoter has been identified as a target of MRTF-
A/SRF, and MRTF-A knockout mice have diminished fibrosis and scar formation 
following MI or angiotensin II treatment.128 Interestingly, MRTF-A activity is known to be 
regulated by actin polymerization which is involved in its nuclear translocation.127,129 Since 
syndecan-4 was found to regulate both transcription of MRTF-A through NFAT and actin 
polymerization, it seems likely that this signalling pathway also will be affected by loss of 
syndecan-4 and may in part be responsible for the impaired myofibroblast differentiation 
of cardiac fibroblasts lacking syndecan-4.  
OPN expression was regulated by syndecan-4 and NFAT (Paper 2). Although OPN 
was traditionally considered an extracellular protein that plays a role in structure and 
function of the extracellular matrix as well as inflammation,130 it may also exist as an 
intracellular variant (iOPN) derived from alternative translation.131 It is worth noting that 
i231KDVEHHQVKRZQWREHHVVHQWLDOIRU7*)ȕ-induced myofibroblast differention.132
Thus the impaired myofibroblast differentiation of cardiac fibroblasts from syndecan-4-/-
mice could be suspected to result from reduced expression of iOPN. However, iOPN did 
not seem necessary for mechanical stress-induced myofibroblast differentiation132 nor have 
we or others54 detected any efIHFWRQ7*)ȕ-induced myofibroblast differentiation by the 
presence or absence of syndecan-4. 
7RJHWKHUZLWKPHFKDQLFDOVWUHVV7*)ȕLVWKHPRVWSRWHQWLQGXFHURIFDUGLDF
myofibroblast differentiation and fibrosis.27,133,26 ,QWHUHVWLQJO\7*)ȕKDUERUVDKHSDULQ-
binding motif and has been shown to bind syndecan-4 on macrophages.134 However to our 
knowledge, no interaction between syndecan-DQG7*)ȕKDVso far been shown in cardiac 
fibroblasts. It has previously been suggested135 and was recently confirmed20 WKDW7*)ȕ
acts as a mechanosensitive factor. T*)ȕLVVHTXHVWHUHGLQWKH(&0LQ a biologically 
LQDFWLYHFRPSOH[WKHODUJHODWHQWFRPSOH[//&,QWHJULQVĮvȕ8 DQGĮvȕ3 exert traction 
forces on the ECM and LLC theUHE\UHOHDVLQJDFWLYH7*)ȕ,Q3aper 1, there was no 
GLIIHUHQFHLQ7*)ȕH[SUHVVLRQE\FDUGLDFILEUREODVWVIURP:7DQGV\QGHFDQ-4-/- mice. 
Hence, it is unlikely that impaired myofibroblast differentiation of cardiac fibroblasts 
lacking syndecan-4 was caused by diminished SURGXFWLRQRI7*)ȕ. However, LI7*)ȕLV
“stored” in the ECM as proposed20,136 WKHUHPD\EHDEOXQWHGUHOHDVHDFWLYDWLRQRI7*)ȕ in 
vivo simply because traction forces are lower (due to impaired myofibroblast 
33
 
differentiation) when syndecan-4 is lacking. Also, syndecan-4 has been found to promote 
DGKHVLRQSURSHUWLHVRIVRPHLQWHJULQVZKLFKPLJKWDIIHFWWKHOLEHUDWLRQRIDFWLYH7*)ȕ39
Whether this mechanism takes place in our in vitro models of myofibroblast differentiation 
is not known. 
 There are several pathways independent of syndecan-4 that are important for 
myofibroblast differentiation,27,137,128,132,138 and myofibroblast differentiation will 
eventually occur even in the absence of syndecan-4. However, syndecan-4 may be one of 
the initial mediators of a mechanical stress-induced response enabling rapid adaptation to 
the surrounding environment. 
Syndecan-4 regulates collagen production and maturation 
Since myofibroblasts are efficient collagen producing cells, impaired cardiac myofibroblast 
differentiation will likely affect collagen amount and composition. Tensile strength and 
structure of the ECM is mainly provided by fibrillar collagens. In the heart, the main 
fibrillar collagen is collagen I (comprising up to 85% of the total amount of collagen) 
followed by collagen III. Indeed, whereas collagen I and III mRNA levels were markedly 
increased in left ventricles of WT mice following 24h AB, this response was absent in 
syndecan-4-/- mice (Paper 1). Thus, we considered it likely that this would translate into 
altered fibrosis at later time points. However, to our surprise total collagen protein amount 
and collagen I and III mRNA levels were similar in WT and syndecan-4-/- mice 7 days 
after AB, suggesting that other pro-fibrotic signaling pathways had taken over collagen 
production in syndecan-4-/- mice.
Traditionally, the increase in myocardial stiffness in the pressure overloaded heart 
has alone been attributed to accumulation of collagen I causing myocardial fibrosis. Also, a 
shift in the ratio of collagen I and III was thought to influence myocardial stiffness.139,140
This view has since been challenged by reports suggesting that the amount of total collagen 
and the collagen I:III ratio does not necessarily translate into changes in myocardial 
stiffness.141 Even though collagen amounts are similar, collagen quality and structure may 
be altered and accumulating data suggest collagen cross-linking to be a determining factor 
for myocardial stiffness.142,143 Cross-linked collagen was in fact reduced in pressure-
overloaded ventricles of mice lacking syndecan-4, indicating impaired maturation of newly 
synthesised collagen. 
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Collagen cross-linking can occur either enzymatically or non-enzymatically. While 
non-enzymatic cross-linking (i.e. of glycated lysine and hydroxylysine collagen residues) 
is generally associated with myocardial stiffening due to age or diabetes,144 collagen cross-
linking induced by mechanical stress seems to be largely attributed enzymatic cross-
linking by the enzyme lysyl oxidase (LOX). LOX is upregulated in the pressure-
overloaded heart,142 and pharmacologically inhibiting LOX decreases collagen cross-
linking and myocardial stiffness.145 Cross-linked collagen is less susceptible to degradation 
by ECM proteases thereby reducing overall collagen turnover. Thus, although no 
difference in MMP2, 9 and 13 mRNA was detected in ventricles from syndecan-4-/- and 
WT mice, collagen degradation may be altered in syndecan-4-/- mice due to less collagen 
cross-linking. This may also partly constitute a possible explanation for the premature left 
ventricular dilatation observed in syndecan-4-/- mice 3 weeks after AB.51
Despite its potentially central role in myocardial stiffening and diastolic 
dysfunction, there are few studies on the mechanisms regulating LOX in the heart. Among 
the identified LOX-inducing factors are TGFȕ146 and angiotensin II.147 Also of interest, 
another proteoglycan called lumican was recently found to upregulate LOX mRNA in 
cardiac fibroblasts in vitro.148 In Paper 2, LOX mRNA and activity was reduced in left 
ventricles from syndecan-4-/- mice 24h and 3 days after AB, respectively, indicating a role 
for syndecan-4 in regulating this enzyme. Syndecan-4-/- mice had substantially reduced 
production of OPN which was recently found to induce LOX expression and activity in 
human cardiac fibroblasts.149 In agreement, we demonstrated in Paper 2 that incubation of 
mouse cardiac fibroblasts with exogenous OPN increased LOX protein. Interestingly, the 
effects of OPN on LOX protein expression were only evident in highly differentiated 
myofibroblasts, suggesting differential effects of OPN depending on cardiac 
fibroblast/myofibroblast phenotype. Although OPN is sparsely expressed in the healthy 
heart, it is rapidly and markedly upregulated in the pressure overloaded heart150 with a 
peak in mRNA levels 24h after AB (Paper 2). At this time point myofibroblast 
differentiation is taking place, but highly differentiated myofibroblasts are most likely not 
present at this early time point. Thus OPN may have other effects on cardiac fibroblasts in 
the initial phase (such as proliferation and survival130) whereas induce LOX expression in 
later stages of the pressure overload response when highly differentiated myofibroblasts 
are present.  
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Our data indicate that collagen cross-linking was enhanced in vitro in the presence 
of the extracellular domain of syndecan-4. Indeed, proteoglycans of the small leucine-rich 
proteoglycan (SLRP) family such as decorin and biglycan are known to bind to and 
stabilise collagen fibrils, and lack of these proteoglycans leads to deranged collagen 
matrices in skin, tendon and elsewhere in the musculoskeletal system.151,152,153,154,155
Collagen cross-linking by LOX was also promoted in the presence of the extracellular 
domain of syndecan-4. In agreement with these results, it has previously been suggested 
that SLRPs156 and cellular fibronectin157 may act as co-receptors for LOX, thereby 
facilitating collagen cross-linking. Moreover, syndecan-4 has been found to regulate the 
cell surface trafficking, localization and activity of another cross-linking enzyme called 
tissue transglutaminase (TG2)158 and the beneficial effect of syndecan-4 deletion on kidney 
fibrosis has been attributed altered function of this enzyme.159  
Myocardial stiffness is determined by syndecan-4 
In Paper 2 we determined the passive tension of the myocardium. An important question is 
how this relates to diastolic function. Although intuitively rather simple, diastolic 
dysfunction is a multi-facetted concept. In general, it can be divided into an active and a 
passive component. The active component (Figure 4, orange box) is associated with
relaxation of cardiomyocytes and involves removal of calcium from the cytoplasm into the 
sarcoplasmic reticulum and extracellular space. This process is carried out mainly by 
energy consuming ion pumps in the sarcoplasmic reticulum membrane and plasma 
membrane, hence the term active phase or component. The passive component (Figure 4, 
green box) manifests itself in later phases of diastole and is determined by mechanical 
properties of the myocardium such as viscosity (viscous stress) and elasticity (passive 
tension) and constitutes the myocardial stiffness. In the heart, viscosity is mainly 
determined by the amount of water present in the myocardium, whereas passive tension is 
largely determined by the cytoskeletal spring-like protein of cardiomyocytes called titin,160
and the composition and structure of ECM.  
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Figure 4. Factors contributing to myocardial diastolic dysfunction.
Diastolic dysfunction involves changes in both the active process i.e. relaxation, and passive forces
(myocardial stiffness) including viscous stress and passive tension of the myocardium. Increased passive 
tension can mainly be attributed modifications of the spring-like protein titin of cardiomyocytes and altered 
amount and composition of the extracellular matrix (ECM), particularly fibrillar collagen.
Diastolic function can be determined from pressure-volume loops (P-V loops). P-V loops 
are difficult to acquire from the AB hearts as the aortic constriction is too tight to allow for 
retrograde insertion of the catheter. Doppler echocardiography also provides information 
about diastolic function in vivo. In Paper 2 we measured early mitral inflow velocity (E) / 
early mitral annular velocity (E´) as an indication of early diastolic function. However, 
E/E´ reflects mainly the active relaxation of cardiomyocytes and may thereby mask or 
prevent an accurate determination of passive myocardial stiffness.161 Thus, even though 
E/E´ was increased (indicating impaired relaxation) in both genotypes following AB, no 
significant differences were observed between WT and syndecan-4-/- mice. 
An important finding in Paper 2 was that passive tension, reflecting intrinsic 
myocardial stiffness, was reduced in myocardial strips from mice lacking syndecan-4. This 
was mainly attributed altered ECM stiffness. In contrast, increased passive myocardial 
stiffness of patients with diastolic dysfunction can often also be attributed modifications of 
the giant spring-like cardiomyocyte protein, titin.162 In the AB mouse model used in this 
study, we did not observe changes in titin isoforms and no major effect of eliminating titin 
function by salt extraction on passive tension, possibly reflecting variability between 
species and etiologies of disease. Moreover, since calcium handling was never addressed in 
these mice and is central for determining the active component of diastole, we cannot draw 
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final conclusions regarding in vivo diastolic function in syndecan-4-/- mice. Regardless, our 
results on intrinsic myocardial passive tension theoretically imply that interfering with 
syndecan-4 function in cardiac fibroblasts would be beneficial with respect to ECM 
stiffness. 
Apart from regulating collagen, syndecan-4 might also affect myocardial stiffness 
through intrinsic properties of the syndecan-4 molecule. The GAG chains of proteoglycans 
have high affinity for water and may thus affect viscoelasticity.163,164 This is especially 
important in cartilage where shock-absorbing properties can be assigned large 
proteoglycans of the hyalectin family. Although we observed significantly increased 
viscous stress of muscle strips from ventricles subjected to 7 days AB (Paper 2) along with 
increased water content (unpublished data), there was no difference in these properties 
between WT and syndecan-4-/- mice, supporting instead a regulatory role for syndecan-4 in 
determining ECM structure and composition.  
Syndecan-4 shedding and inflammation in the pressure-overloaded heart 
Enzymatic shedding of syndecan-4 has been implicated as part of the innate immune 
response which is involved in heart failure development.165,166 The innate immune system 
is the first line of defense against pathogens and becomes activated when cell surface toll-
like receptors (TLRs) recognise unspecific highly conserved structural motifs of pathogens 
called pathogen-associated molecular patterns (PAMPs; eg. LPS) and thereby induce an 
inflammatory response. An innate immune response is also triggered during tissue injury 
by specific danger-associated molecular patterns (DAMPs), often comprising fragments of 
ECM components (e.g. hyaluronic acid) that are released from the host.167 In Paper 3,
triggering innate immunity by stimulation with LPS upregulated syndecan-4 in a TLR4-
dependent manner both cardiomyocytes and fibroblasts and enhanced syndecan-4 
VKHGGLQJ,QWHUHVWLQJO\WKHWZRF\WRNLQHV71)ĮDQG,/-ȕWKDWDUHUDSLGO\LQFUHDVed by 
pressure overload had a similar effect on syndecan-4 in vitro to that of LPS, suggesting 
activation of signalling pathways of the innate immune system. Thus, although LPS is not 
present in the pressure-overloaded heart, it serves well as a model system when studying 
the innate immune response.  
As demonstrated in Paper 3, left ventricular pressure overload caused T cell 
infiltration 1-3 weeks after AB in WT mice indicating that T cell recruitment is a part of 
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the late, rather than the early response to pressure overload. At these time points, T cell 
infiltration was reduced in mice lacking syndecan-4 indicating a defective innate immune 
response in the absence of syndecan-4. In agreement, syndecan-4-/- mice have higher 
mortality to LPS when compared to WT mice.134 Considering that syndecan-4 is widely 
expressed,168,169 there are several possible explanations for reduced T cell infiltration in 
syndecan-4-deficient mice: lack of the chemotactic gradient provided by shed syndecan-4 
in the myocardial tissue; lack of full-length syndecan-4 on endothelial cells thus reducing 
immune cell adherence and infiltration, or lack of full-length syndecan-4 on T cells thus 
affecting migration. Regardless, results obtained from the syndecan-4-/- mouse provide 
evidence that syndecan-4 expression and shedding are involved the immune response of 
the pressure-overloaded heart.  
The regulation of syndecan-4 shedding involves extracellular proteases, many of 
which are produced by cardiac fibroblasts and myofibroblasts and are upregulated in the 
pressure-overloaded heart.170 These include matrix metalloproteases (MMPs) and 
ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs).94 Syndecan-
4 shedding was to some degree dependent on intact HS GAG attachment sites, indicating 
that syndecan-4 shedding is primarily regulated by enzymes dependent on interacting with 
HS GAG chains. Of interest, activation of pro-MMP2 by thrombin has been found to 
depend on heparan sulfate171 and as shown in Paper 2, MMP2 was upregulated in response 
to pressure overload. In Paper 3, cardiac fibroblasts treated with a NF-ƸB blocker had 
reduced expression and shedding of syndecan-4. This might suggest that proteases that 
shed syndecan-4 are transcribed by NF-Ƹ%In vascular smooth muscle cells syndecan-4 
shedding has been found to be regulated by MAP kinases (ERK1/2 and JNK).99 However, 
the responsible proteases were not identified.  
Syndecan-4 ectodomain is not found in normal plasma but appears in fluids 
surrounding injured tissue, suggesting a role in the wound healing response.172
Furthermore, it has been detected in plasma of patients after myocardial infarction95 and 
heart failure.96 Due to the increased syndecan-4 shedding in the patients with end-stage 
heart failure studied in Paper 3, we suspect that the increased syndecan-4 ectodomain 
plasma levels could originate from the heart. However, the source of this shedding might
also be endothelial cells considering that plasmin and thrombin (proteases involved in 
coagulation and fibrinolysis during tissue injury) are also known syndecan-4 
“sheddases”.173 At least during early stages of left ventricular pressure overload (24h, 
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Paper 1), shed syndecan-4 was not detected in blood. In Paper 3, syndecan-4 shedding was 
increased in the myocardium 1 week after AB, and further enhanced 3 weeks after AB, 
indicating that syndecan-4 shedding is a process taking place at progressed stages of 
cardiac remodelling where also inflammation is more prominent, compared to syndecan-4 
expression which is a rapid response occurring within the first 24h of pressure overload.  
Interestingly, T helper lymphocytes have recently been implicated in the regulation 
of ECM remodelling of the pressure-overloaded heart, inducing collagen cross-linking and 
diastolic dysfunction174,175 through activation of lysyl oxidase.176 Accompanying the 
increased myocardial stiffness, was an increase in T helper cell marker CD4 7 days after 
AB. Hence, the reduced collagen cross-linking and LOX activity observed in Paper 2 
might also partly be explained by less T helper cell infiltration. Similar to what has been 
found for the cross-linking enzyme TG2, syndecan-4 shedding might also promote 
collagen cross-linking by transporting LOX into the ECM in response to injury or 
mechanical stress.177,178,179
In Paper 3 we show that LPS-induced shedding of syndecan-4 reduced focal-
adhesion size. Based on our results in Paper 1 and 2, this will likely interfere with 
downstream signalling of syndecan-4 hence reducing LOX expression via OPN. Reduced 
focal adhesion size and stability will most likely also affect migration properties and 
reduce myofibroblast differentiation of cardiac fibroblasts which is somewhat 
contradictory to the role of full-length syndecan-4.  
The role of syndecan-4 during the sequence of events occurring in response to left 
ventricular pressure overload.
In attempt to clarify the role of syndecan-4 in the pressure-overloaded heart and based on 
the results obtained in this thesis, the following section will deal with placing syndecan-4 
and its multiple roles in a timely context following induction of pressure overload (Figure 
5), with particular focus on cardiac fibroblasts and ECM remodelling.  
Pressure overload of the left ventricle due to aortic stenosis or hypertension, is 
mimicked by aortic banding (AB). This triggers a rapid increase in IL-ȕDQG71)Į
mRNA (2h post AB, unpublished data), cytokines involved in a so-called “sterile” immune 
response of the innate immune system. Although the source of this cytokine production is 
not entirely clear, it is likely that both cardiomyocytes and cardiac fibroblasts contribute.  
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Cardiac fibroblasts start proliferating (proliferating cell nuclear antigen mRNA upregulated 
6h post AB, unpublished results) and increase syndecan-4 expression (6h post AB, 
unpublished data) in response to stimulation with IL-ȕDQG71)Į
The presence of more syndecan-4 in cardiac fibroblasts increases attachment to the 
ECM, thereby enhancing the overall mechanosensing by syndecan-4. Mechanical stress 
leads to dephosphorylation of the cytoplasmic domain of syndecan-4 thereby enabling 
binding and activation of calcineurin. Calcineurin dephosphorylates NFAT which can then 
translocate to the nucleus and transcribe target genes involved in myofibroblast 
differentiation such as MRTF-A, and production of ECM molecules including collagen III 
and OPN.  
OPN is markedly increased in the pressure-overloaded heart of WT mice and was 
found to induce LOX production in cardiac myofibroblasts which are prevalent in the 
myocardium 3 days after AB. At this time point myocardial LOX activity was increased, 
hence inducing collagen cross-linking which was clear 7 days after AB. In vitro
experiments with the extracellular domain of syndecan-4 suggest a role in collagen fiber 
assembly and cross-linking by LOX at the cell surface. Hence syndecan-4 may have a dual 
role in regulating collagen structure and tensile strength. Importantly myocardial passive 
tension of the ECM is markedly increased after 7 days with pressure overload. This 
increased myocardial stiffness (and the accompanied hypertrophic remodelling of 
cardiomyocytes) enables the heart to perform under conditions of increased myocardial 
pressure but will eventually compromise diastolic function.  
At this stage, syndecan-4 shedding is initiated. This may serve to abrogate 
syndecan-4-induced myofibroblast differentiation, causing reduction in focal adhesion size 
and loss of syndecan-4 mechanosensing activity. However, the shed ectodomain of 
syndecan-4 seems also to have activities of its own, possibly creating a chemotactic 
gradient enhancing the T cell infiltration of the myocardium observed 21 days after AB 
which may further affect ECM remodelling.175  
This is a coarse and somewhat speculative summary of our results in order to 
simplify the confusing (and to some extent contradicting) roles of syndecan-4. Syndecan-4 
is here put in the center of events leading to heart failure. However, it is clear that 
numerous factors are involved and supplement the proposed model.  
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Syndecan-4 as a therapeutic target
The novel finding of Paper 2 that syndecan-4 has profound effects on myocardial stiffness 
renders it an attractive drug target for treatment of diastolic dysfunction. However, as with 
most signalling pathways, syndecan-4 signalling does not seem to work as a simple “on-
off” switch. As such, complete deletion of syndecan-4 may inhibit myocardial stiffening,
but also accelerates heart failure development and left ventricular dilatation.51 This clearly 
underscores the need for more knowledge regarding syndecan-4 in the heart, including 
identification of binding partners, monitoring spatial and temporal dynamics of syndecan-4 
signalling and understanding the role of syndecan-4 shedding. Another future challenge 
will be to identify differential traits between syndecan-4-dependent signalling in cardiac 
fibroblasts and cardiomyocytes to specifically target processes leading to changes in 
passive tension and limit an exacerbated fibrosis while keeping the critical adaptive 
hypertrophic response of cardiomyocytes to pressure overload intact. Thus, although 
syndecan-4 is merging as an attractive target in anti-fibrotic180 and cardiac therapy,1 further 
studies are necessary to determine when and where to intervene to achieve beneficial 
outcome of a potential future treatment. 
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Conclusions
The results presented in this thesis demonstrate a role for syndecan-4 in determining 
cardiac fibroblast function and phenotype, ECM remodelling and myocardial stiffening of 
the pressure overloaded heart. 
In Paper 1 we show that syndecan-4 regulates myofibroblast differentiation of 
cardiac fibroblasts in response to mechanical stress, as seen by impaired organisation of 
SMA stress fibers and reduced FA size. The cytoplasmic domain of syndecan-4 was 
dephosphorylated in response to mechanical stress leading to activation of 
calcineurin/NFAT signalling and upregulation of genes defining the myofibroblast 
phenotype such as MRTF-A, and involved in ECM remodelling such as collagen.  
Using syndecan-4-/- mice, we show in Paper 2 that ECM production is blunted and 
collagen cross-linking reduced when syndecan-4 is lacking. Our data suggested a dual role
for syndecan-4 in collagen cross-linking: promoting lysyl oxidase expression by 
upregulating OPN in response to mechanical stress, and by direct interaction of syndecan-4 
ectodomain with collagen I, thereby facilitating LOX cross-linking activity. Importantly, 
these effects translated into reduced myocardial passive stiffness in syndecan-4-/- mice 
which may have consequences for diastolic function of the heart.  
Finally, in Paper 3 we show that IL-ȕDQG71)Į, which are rapidly increased in 
the pressure-overloaded heart, regulated syndecan-4 expression via NF-Ƹ%VLJQDOLQJ. At 
more advanced stages of cardiac remodelling, syndecan-4 shedding occurred, possibly 
affecting myofibroblast function and T cell infiltration of the pressure-overloaded heart. 
Importantly, syndecan-4 shedding was elevated in failing human hearts, supporting 
syndecan-4 as a potential target for treatment of heart failure patients.  
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Abstract
Aim: Diastolic dysfunction is central to the development of heart failure. To date, there is no 
effective treatment and only limited understanding of its molecular basis. Recently we 
showed that the transmembrane proteoglycan syndecan-4 increases in the left ventricle after 
pressure overload in mice and man; and that syndecan-4 via calcineurin/NFAT promotes 
myofibroblast differentiation and collagen production upon mechanical stress. The aim of this 
study was to investigate if syndecan-4 affects collagen cross-linking and myocardial 
stiffening in the pressure-overloaded heart.
Methods and Results: Aortic banding (AB) caused concentric hypertrophy and increased 
passive tension of left ventricular muscle strips, responses that were blunted in syndecan-4-/-
mice. Disruption of titin anchoring by salt extraction of actin and myosin filaments revealed 
that the effect of syndecan-4 on passive tension was due to extracellular matrix remodeling. 
Expression and activity of the cross-linking enzyme lysyl oxidase (LOX) increased with 
mechanical stress and was lower in left ventricles and cardiac fibroblasts from syndecan-4-/-
mice, which exhibited less collagen cross-linking after AB. Expression of osteopontin (OPN), 
a matricellular protein able to induce LOX in cardiac fibroblasts, was upregulated in hearts 
after AB, in mechanically-stressed fibroblasts and in fibroblasts overexpressing syndecan-4, 
calcineurin or NFAT, but downregulated in fibroblasts lacking syndecan-4 or after NFAT 
inhibition. Interestingly, the extracellular domain of syndecan-4 facilitated LOX-mediated 
collagen cross-linking.  
Conclusions: Syndecan-4 exerts a dual role in collagen cross-linking, one involving its 
cytosolic domain and NFAT signaling leading to collagen, OPN and LOX induction in 
cardiac fibroblasts; the other involving the extracellular domain promoting LOX-dependent 
cross-linking. 
3 
 
1. Introduction
Diastolic dysfunction is central to the development of heart failure, a common and fatal 
disease.1 Defined by abnormal relaxation and/or decreased compliance of the ventricles, 
diastolic dysfunction results in impaired filling of the heart. While, in healthy individuals, the 
major risk factor for diastolic dysfunction is age, any condition that leads to stiffening of the 
ventricles can result in diastolic dysfunction, e.g. pressure overload as in hypertensive and
aortic stenosis patients, or diabetes. Despite improved medical options for cardiovascular 
disease, there is currently no effective treatment for diastolic dysfunction, reflecting the need 
for a better understanding of its molecular basis. Next to modifications of the elastic titin 
springs of cardiomyocytes2, changes in extracellular matrix (ECM) composition and structure 
are important determinants of myocardial stiffening3.
Cardiac fibroblasts are the major non-muscle cells of the ventricular myocardium and 
are key players in myocardial stiffening. During ventricular remodeling following sustained 
periods of pressure overload, cardiac fibroblasts become activated and start producing 
excessive amounts of ECM proteins, such as fibrillar collagens, eventually resulting in 
increased myocardial fibrosis.4 The activated fibroblast acquires smooth muscle-like features 
including expression of smooth muscle D-actin (SMA) and SM22 and is therefore referred to 
as myofibroblast,5 as well as increases expression of platelet-GHULYHGJURZWKIDFWRUUHFHSWRUȕ
3'*)5ȕ6,7  
Recent clinical studies have questioned whether overexpression of collagen can alone 
explain the increased myocardial stiffness, and collagen cross-linking has been suggested as 
an additional contributing factor.8,9 While non-enzymatic cross-linking (i.e. of glycated lysine 
and hydroxylysine collagen residues) is generally associated with myocardial stiffening due 
to age or diabetes,10 collagen cross-linking induced by mechanical stress seems to be largely 
attributed to enzymatic cross-linking by the enzyme lysyl oxidase (LOX), which is 
upregulated in the pressure-overloaded heart.8 Despite its potentially central role in 
myocardial stiffening, little is known regarding mechanisms regulating LOX in the heart. 
Interestingly, the matricellular protein OPN was recently found to induce LOX expression 
and activity in cardiac fibroblasts.11 Although sparsely expressed in the healthy heart, OPN is
dramatically increased in mice subjected to pressure overload by aortic banding (AB).12
Recent work in our laboratory demonstrated that expression of the transmembrane 
heparan sulphate proteoglycan syndecan-4 increases in the left ventricle after pressure 
overload in mice5 and man,13 through inflammatory mediators such as tumor necrosis factor 
71)Įand interleukin (IL)-ȕ14 Also, that in response to mechanical stress, syndecan-4 
engages the calcineurin/NFAT (Nuclear Factor of Activated T-cells) signaling pathway in 
cardiac fibroblasts to promote ECM production and differentiation into activated 
myofibroblasts.5 Thus, one specific aim of this study was to examine whether syndecan-4 
expression and/or signaling has a direct impact on myocardial stiffness. A second aim of this 
study was to explore if syndecan-4 may be important for collagen cross-linking. Previous 
work has shown that NFAT activation leads to the induction of OPN expression in vascular 
smooth muscle cells.15 We therefore hypothesized that OPN might be a down-stream target of 
syndecan-4/NFAT signaling in cardiac fibroblasts and that enhanced OPN expression after 
pressure overload, by virtue of an increase in LOX expression and activity, may promote 
collagen cross-linking and myocardial stiffening of the heart. 
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2. Methods
A detailed description of the methods is provided in supplementary material online.
2.1 Mouse Model of Pressure Overload
AB or sham operations followed by echocardiography were performed on adult wild-type 
(WT) and syndecan-4 knockout (syndecan-4-/-) mice16 as previously described13,17 and mice
were sacrificed by cervical dislocation after 24h, 3 days or 7 days after AB. Animals were 
handled according to the National Regulation on Animal Experimentation in accordance with 
approved protocol (ID#2845) and the Norwegian Animal Welfare Act, and conform the NIH 
guidelines (2011).  
2.2 Mechanical measurements
Left ventricular muscle strips were skinned and passive tension, reflecting the elastic 
components of the muscle, was determined by stretching from slack length (L0) to 30% L0
while measuring force. Salt extraction was performed as previously described.18 Viscous 
stress, reflecting the stretch velocity sensitive component of the muscle, was determined as 
peak force upon stretching minus steady-state force, divided with cross-sectional area.
2.3 Titin gels
Samples prepared from snap frozen left ventricular tissue were loaded on agarose-
strengthened 2% SDS-polyacrylamid gels19 and titin N2B and N2BA isoforms detected at 
3000kDa and 3200kDa, respectively, by coomassie brilliant-blue staining.  
2.4 Electron microscopy
Mouse hearts were fixed in 3.5% glutaraldehyde (Sigma) in 0.1 M cacodylate buffer (pH 7.2; 
Sigma) by perfusion and small pieces of the left ventricular wall were prepared for electron 
microscopy. For quantification, 5 images (x440) per section were analyzed to determine non-
cardiomyocyte fractions, and 24-30 images (x2900) per section of the non-cardiomyocyte 
fraction to determine the areas of fibroblast nuclei (reflecting number of fibroblasts) and 
blood vessels. Two-three sections per animal were inspected.  
2.5 Collagen cross-linking and quantification
Total collagen was determined by hydroxyproline content measured by HPLC. Insoluble 
cross-linked collagen was quantified as previously described.20 Briefly, soluble collagen 
assessed using colorimetric and enzymatic procedures was subtracted from total collagen 
determined by staining with picrosirius red and normalized to total protein content 
determined by fast green staining. For visualization of total and cross-linked collagen, 
sections from formalin-fixed left ventricles were stained with picrosirius red and examined 
using non-polarized and circularly polarized light, respectively.
2.6 Fibroblast Cell Culture
Cardiac fibroblasts were isolated as previously described5 and used at passage 2 to limit in 
vitro effects on fibroblast phenotype. For overexpression, an adenoviral vector containing 
mouse syndecan-4 (Applied Biological Materials Inc, Richmond, Canada) was used. The 
NFAT blocker A-285222 was kindly provided by Abbott Laboratories (1μmol/L; Abbott 
Park, IL). CelOVZHUHVWLPXODWHGZLWKQJPO7*)ȕ0HUFN0LOOLSRUH'DUPVWDGW
Germany) and 250 ng/ml OPN (Cat. no.120-35; Peprotech, Hamburg, Germany). 
2.7 Gene Expression Analysis 
RNA was extracted, cDNA synthesized and real-time performed as previously described.5
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2.8 Immunoblotting
Immunoblotting was performed on left ventricle homogenates as previously described.21
Anti-osteopontin (IBL, Hamburg, Germany) and anti-LOX (NB100-2527, Novus Biologicals, 
Littleton, CO) were used as primary antibodies.  
2.9 Immunocytochemistry and immunohistochemistry
Cells grown on fibronectin-coated glass cover slips were fixed in 4% paraformaldehyde and 
stained using mouse-anti-SMA (Sigma, Schnelldorf, Germany) and alexa fluor 488-
secondary anti-mouse antibodies (Invitrogen, Paisley, UK). Formalin-fixed myocardial tissue 
sections (4 μm) were stained for SMA (DAKO, Glostrup, Denmark) and platelet-derived 
growth factor receptor ȕ3'*)5ȕ&HOO6LJQDOLQJ'DQYHUV0$DQGYLVXDOL]HGXVLQJ
secondary antibodies conjugated to horseradish peroxidase (HRP). 
2.10 Lysyl oxidase activity assay 
LOX activity was measured in left ventricular tissue and cardiac fibroblasts with a 
fluorometric LOX activity assay (Abcam, Cambridge, UK) according to the manufacturer’s 
instructions. 
2.11 In vitro collagen fiber formation assay 
The extracellular domain of syndecan-4 (1-4μg, Sino Biological Inc., Beijing, China) was
mixed with 10μg collagen I with or without recombinant human lysyl oxidase homolog 2 
(0.1μg, LOXL2 with activity > 2pmol/min/μg, R&D systems, Abingdon, UK). The mixture 
was incubated at 37ºC for 24-72h before performing turbidimetry and electron microscopy.  
2.12 Statistics
Data are expressed as means ± standard deviation (S.D.) unless otherwise specified in the 
figure legends. Statistical analysis was performed using GraphPad software (Prism 5). The 
use of parametric or non-parametric tests was based on results from analyses of distributions. 
Statistical significance was determined using Mann-Whitney test and Kruskal-Wallis 
followed by Dunn’s multiple comparison test for non-parametric data; or Student’s t-test and
two-way ANOVA followed by Bonferroni post hoc tests for normally distributed data. 
Pearson’s test was used for correlation analyses. ***P<0.005, **P<0.01, *P<0.05. 
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3. Results
3.1 Myocardial stiffness is reduced in mice lacking syndecan-4 
AB caused hypertrophic remodeling as determined by echocardiography (Supplementary 
Table 1) which was accompanied by an increase in passive tension (Figure 1A). Along with 
reduced concentric hypertrophic remodeling in syndecan-4-/- mice (Supplementary Table 1), 
which is in accordance with our previous findings,13 passive tension was significantly lower 
in myocardial tissue from syndecan-4-/- mice (Figure 1A). Another factor contributing to 
myocardial stiffness is the viscosity of the tissue. Viscous stress was increased following AB 
(Figure 1B) but it was not affected by the genotype of the mice. Cardiomyocytes and ECM 
both contribute to passive tension. In cardiomyocytes, passive tension is mainly determined 
by the sarcomeric “spring-like protein” titin.2 To investigate the cardiomyocyte contribution 
to the observed reduction of passive tension in syndecan-4-/- mice after pressure overload, we 
measured the ratios between the longer and more compliant titin isoform N2BA and the 
shorter and stiffer N2B isoform. N2BA:N2B ratios were unchanged by AB or lack of 
syndecan-4 (Figure 1C). To study whether the reduced passive tension in syndecan-4-/- mice 
could be due to changes in the ECM, we performed salt extraction of actin and myosin 
filaments, a treatment that destroys the anchoring points of titin leaving the ECM to account 
for the remaining passive tension.18 Indeed, ECM-dependent passive tension was 
significantly lower in muscle strips from syndecan-4-/- mice compared to WT (Figure 1D). 
The complete disruption of sarcomere structure by salt extraction was verified using electron 
microscopy (Figure 1E). The area of myocardial tissue consisting of cardiomyocytes vs. non-
cardiomyocyte (non-CM) fraction seemed unaltered by AB or lack of syndecan-4 
(Supplementary Table 2).
3.2 Increased expression of syndecan-4 promotes cardiac myofibroblast differentiation  
As we showed in neonatale cardiac fibroblasts,5 lack of syndecan-4 had profound effects in 
adult cardiac fibroblasts. While adult syndecan-4 deficient cardiac fibroblasts exhibited 
virtually no SMA fiber formation after 48h on fibronectin, fibroblasts from WT mice had 
clear SMA fibers (Figure 2A). This impaired ability to undergo myofibroblast differentiation 
of cells lacking syndecan-4 was restored by adenoviral-transduction of syndecan-4 (Figure 
2A). Further, overexpression of syndecan-4 in WT cardiac fibroblasts resulted in enhanced 
SMA fiber formation (Figure 2A). Myofibroblast differentiation was also impaired in vivo as
GHPRQVWUDWHGE\UHGXFHGVWDLQLQJRI60$DQG3'*)5ȕ)LJXUH%1HJDWLYHDQGSRVLWive controls 
are included in Supplementary Figure 1.
We also examined whether changes in fibroblast proliferative capacity and 
consequently a larger number of fibroblasts in the non-CM fraction could account for the 
reduced myocardial passive tension observed in syndecan-4-/- mice after pressure overload. 
However, as shown in figures 2C and D (24h and 7 days after AB, respectively), expression 
of the cell cycle S-phase marker PCNA (proliferating cell nuclear antigen) was not different 
in cardiac homogenates from WT and syndecan-4 deficient mice. Given the limited capacity 
of cardiomyocytes to re-enter the cell-cycle22,23 most of the PCNA signal could be attributed 
to cell proliferation in the non-CM fraction. Further, lack of syndecan-4 did not affect the 
proliferative capacity of cardiac fibroblasts in vitro, as assessed after 48h or 72h after culture 
on fibronectin coated plates (Figure 2E). This was consistent with EM data suggesting no 
differences in the number of cardiac fibroblasts in the non-CM fraction between genotypes 
(Supplementary Table 2).  
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3.3 Collagen cross-linking is impaired in left ventricles of syndecan-4-/- mice following 
pressure overload
Total collagen contents as determined by HPLC were significantly increased 7 days after AB,
but this response was unaffected in syndecan-4-/- mice (Figure 3A). A similar pattern was 
observed for the expression of collagen I and III mRNA at this time-point (Figure 3D-E). 
This is in contrast with recent data from our group showing that absence of syndecan-
4/CaN/NFAT signaling impairs collagen I and III mRNA expression 24h after AB,5
suggesting a delayed induction of collagen mRNA in the syndecan-4 null mice, which is no 
longer apparent at later time-points. While AB caused dramatic changes in the expression of 
several of the main enzymes that regulate collagen degradation (MMP2, MMP13, TIMP1 and 
TIMP2), these and also levels of MMP9 were not affected by the genotype of the mice 
(Supplementary Figure 1). To investigate if altered collagen cross-linking could contribute to 
the observed differences in passive tension, we measured soluble collagen content and 
calculated the amount of insoluble cross-linked collagen. Indeed, insoluble collagen was 
increased in left ventricles after AB, but this response was blunted in syndecan-4-/- mice 
(Figure 3C). For visualization purposes, left ventricular tissue sections 7 days after AB were 
stained with picrosirius red and examined using polarized light. Images show increased total 
and cross-linked collagen after AB in WT mice, while less apparent responses in sections 
from syndecan-4 deficient mice (Figure 3B and D). Other structural matrix proteins may also 
be altered in syndecan-4-/- mice and thereby, contribute to changes in compliance, such as 
elastin. However, mRNA and protein levels of elastin, despite being increased after AB, they 
were not affected by the genotype of the animals (Supplementary Figure 3A-B). Moreover, 
elastin levels decreased during myofibroblast differentiation (Supplementary Figure 3C). 
3.4 Lysyl oxidase expression and activity are reduced in left ventricles and cardiac 
fibroblasts from syndecan-4-/- mice
AB resulted in significantly increased LOX mRNA levels in the left ventricles of syndecan-4 
competent mice 24h after surgery (Figure 4A). This response was blunted in the ventricles of 
syndecan-4 deficient mice. Culture of cardiac fibroblasts from WT mice on fibronectin-
coated plates also resulted in a time-dependent increase in LOX mRNA expression, while 
culture of fibroblasts from syndecan-4 deficient mice failed to induce any changes in LOX 
mRNA expression (Figure 4B). Myocardial LOX activity was also increased after AB in WT 
mice, but the same was not observed in tissue from syndecan-4 deficient mice (Figure 4C).
3.5 Pressure overload and mechanical stress induce OPN expression in a syndecan-
4/calcineurin/NFAT-dependent manner  
Pressure overload resulted in a rapid and dramatic induction of OPN expression 24h after 
AB, both at the mRNA (>600-fold) and protein (6.9-fold) level (Figure 5A-B). OPN mRNA 
remained significantly elevated 7 days after AB, although levels were lower than those at 24h 
(Figure 5C). In mice lacking syndecan-4, the induction of OPN by pressure-overload was 
clearly blunted both at 24h and 7 days (Figure 5A-C). OPN mRNA levels were positively 
correlated to LOX mRNA levels in left ventricular tissue of WT mice (Figure 5D). A similar 
induction of OPN was observed when cardiac fibroblasts from WT mice were mechanically 
stressed by culture on fibronectin coated plates, while this response was absent in cardiac 
fibroblasts from syndecan-4-/- mice (Figure 5E). Conversely, overexpression of syndecan-4 in 
HT1080 fibroblasts increased OPN mRNA levels (Figure 5F). We have previously 
demonstrated that upon mechanical stress, syndecan-4 engages the calcineurin-dependent 
transcription factor NFAT5 and that NFAT activation regulates OPN expression in vascular 
smooth muscle cells.15 Here we found that OPN mRNA levels were elevated in HT1080 
fibroblasts overexpressing calcineurin (Figure 5F), but reduced in cardiac fibroblasts treated 
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with the NFAT blocker A-285222 (Figure 5G). Furthermore, overexpression of NFATc4, 
clearly increased OPN mRNA expression in HT1080 fibroblasts and this effect was more 
pronounced after mechanical stress (Figure 5H). 
Stimulation with exogenous OPN for 24h has recently been shown to increase pro-
LOX protein expression and LOX activity in cardiac human fibroblasts.11 Here we 
demonstrate increased LOX protein expression after OPN stimulation in mouse cardiac 
ILEUREODVWVWKDWKDGEHHQFXOWXUHGRQILEURQHFWLQFRDWHGSODWHVZLWK7*)ȕ6XSSOHPHQWDU\
Figure 4A-B), a protocol that promotes myofibroblast differentiation.5 Lack of syndecan-4 
had no impact on OPN-induced LOX (Supplementary Figure 4A-B), confirming that the 
effects are downstream of OPN and do not involve signaling via syndecan-4. Interestingly, 
myofibroblast differentiation also yielded significantly increased expression of known OPN 
receptors including LQWHJULQVĮv and ȕ1, and CD44 (Supplementary Figure 4C). 
3.6 The extracellular domain of syndecan-4 interacts with collagen fibrils and promotes 
collagen cross-linking by LOX
We next examined the effect of the extracellular domain of syndecan-4 (ECsyn4) on collagen 
I fiber formation in a test tube. Incubation of collagen I at 37ºC for 72h with increasing 
concentrations of ECsyn4 resulted in a dose-dependent increase in turbidity measured as 
optical density at 340nm (Figure 6A). Incubation of the highest concentration of ECsyn4 
alone (4μg) failed to increase optical density. At the electron microscopy level, collagen 
fibrils appear similar in thickness and structure in samples containing the mix of collagen and 
ECsyn4, and collagen alone (Figure 6B). However, only the samples containing the mix of 
collagen and ECsyn4 exhibited extensive dense networks surrounding the collagen fibrils 
(marked with asterisks in Figure 4B). Addition of LOX to samples containing collagen 
caused formation of large insoluble protein aggregates after 48h due to collagen cross-linking 
and formation of extensive collagen fiber networks as observed by electron microscopy 
(Figure 6D). Turbidity of these samples after 24h, when the collagen was still in solution, 
further increased with the addition of ECsyn4 (Figure 6C) and resulted in the appearance of 
structures resembling small collagen fibers between the thicker collagen fibers (Figure 6D; 
arrows). In samples containing collagen and LOX, similar dense structures to those seen in 
samples without LOX but with ECsyn4, where observed (Figure 6D; asterisks). Taken 
together, these results suggest that the extracellular domain of syndecan-4 promotes collagen 
fiber formation, possibly facilitating collagen cross-linking by LOX. 
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4. Discussion
Since the recognition of diastolic dysfunction as a common and prominent feature of the 
failing heart, there has been an increased focus on understanding the molecular mechanisms 
underlying myocardial stiffening as a cause of diastolic dysfunction. With this study we 
demonstrate the importance of syndecan-4 in determining passive tension of the myocardium 
following pressure overload. Our understanding of how this is achieved in the mouse model 
used here is schematically presented in Figure 7: Within the first 24h after AB, a rapid 
upregulation of syndecan-4 takes place in the left ventricle of the heart. In this context of 
abundant syndecan-4 expression, cardiac fibroblasts will more readily sense the increased 
mechanical stress and engage the calcineurin/NFAT signaling pathway to promote 
myofibroblast differentiation.5 While syndecan-4 levels will eventually return to normal 
levels 3 weeks after AB (this study and 14), a series of events triggered by mechanical stress-
induced syndecan-4 signaling will contribute to increased myocardial stiffness of the left 
ventricle. Activated myofibroblasts will produce excessive amounts of ECM proteins, 
including collagen I and III, and OPN. A concomitant increase in the expression and activity 
of LOX will result in increased collagen cross-linking and hence, increased passive tension 
(stiffness) 7 days after AB. In our previous work, we demonstrated that phosphorylation of 
serine 179 in the cytoplasmic part of syndecan-4 was required for calcineurin/NFAT 
activation.5 Here we show that the extracellular domain of syndecan-4 seems also to be 
involved in determining ECM stiffness by interacting with collagen fibers and facilitating 
collagen cross-linking by LOX. 
Deletion of syndecan-4 had a striking effect on myocardial stiffness, with passive 
tension being clearly lower in myocardial muscle strips from mice lacking syndecan-4 after 
AB. There are two main contributors to passive tension in the left ventricle: the giant “spring-
like” protein of the cardiomyocyte sarcomere, titin,24 and the ECM. Considering the location 
of syndecan-4 in the costameres overlaying the Z-disc of cardiomyocytes,25 a site to which 
titin is attached, we might expect an effect of syndecan-4 deletion on titin function. To 
examine this, we eliminated the contribution of titin to passive tension by performing 
myofilament extraction of muscle strips. In agreement with a previous report26 titin accounted 
for about one third of the total passive tension of left ventricular tissue from sham-operated 
mice. In contrast, passive tension of pressure-overloaded left ventricles was almost entirely 
accounted for by the ECM. Importantly, the relative decrease in passive tension following 
titin disruption was similar in muscle strips from WT and syndecan-4-/- mice, suggesting 
intact titin function in mice lacking syndecan-4, and that the observed difference in passive 
tension was caused by altered ECM remodeling. 
Although results gained in vitro from muscle strips do not translate directly into the 
mechanical properties of the whole heart, they strongly support an important role for the 
ECM in myocardial stiffening in response to elevated pressure. In patients with congenital 
heart disease, elevated end-diastolic pressure is accounted for by higher stiffness of both 
myocytes and ECM.27 Although increased myocyte stiffness did not prevail in the AB mouse 
model used in this study (reflecting variability between species and etiologies of disease), the 
molecular processes of ECM remodeling investigated here are likely to apply also in humans 
with pressure-overloaded ventricles. 
One exciting finding in this study was the effect of syndecan-4 deletion on collagen 
cross-linking. In addition to collagen amount, the structure of collagen has a major impact on 
the tensile strength of the ECM and passive tension of the left ventricle. This is demonstrated 
in muscle strips from pressure-overloaded and volume-overloaded congenital heart failure 
patients where, despite equal levels of collagen, ECM stiffness was higher in patients with 
pressure-overloaded ventricles due to differences in collagen cross-linking.27 Also in 
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hypertensive patients, collagen cross-linking correlated with elevated left ventricular filling 
pressures, whereas collagen amount did not.8 We here found that mice lacking syndecan-4 
have reduced LOX expression and activity in vivo and lower degree of collagen cross-linking, 
suggesting a regulatory role for syndecan-4 of this enzyme. A similar link has been found 
between syndecan and another ECM-crosslinking enzyme, tissue transglutaminase, which 
exhibited decreased activity in syndecan-1-/- mice following myocardial infarction28 and in 
syndecan-4-/- mice during kidney tissue remodeling.29
Despite its apparently critical role in myocardial stiffening little is known regarding 
mechanisms regulating LOX in the heart. Recently, OPN was found to induce LOX 
expression and activity in human cardiac fibroblasts.11 Here we demonstrate that OPN 
induces LOX also in mouse cardiac fibroblasts and that the effects are potentiated under 
conditions leading to myofibroblast differentiation (i.e. culture on fibronectin coated plates or 
pre-FRQGLWLRQHGZLWK7*)ȕIncreasing evidence also suggest an important role for OPN in 
the development of cardiac fibrosis.30,31,11,32 OPN correlates to cross-linked collagen in 
hypertensive heart disease patients and to left ventricular chamber stiffness in pressure-
overloaded rats. OPN-deficient mice fail to develop fibrosis in response to AngII treatment33
and have reduced collagen accumulation after acute myocardial infarction.32 Cardiac OPN 
expression can be triggered by mechanical stress as demonstrated in this study, which also
suggests that syndecan-4/NFAT signaling is involved in the regulation of OPN in the context 
of pressure overload.  
Recently, syndecan-4 signaling was shown to inhibit apoptosis and regulate NFAT 
activity after myocardial infarction,34 but in this context, syndecan-4-/- mice exhibited 
increased NFAT activity, as opposed to the reduced activity we report in syndecan-4-/- mice 
after pressure overload. This discrepancy is intriguing and may be at least in part be 
explained by the different nature of the experimental models. While the cardiac remodeling 
process is predominantly triggered by inflammation and apoptosis in MI, it is in the pressure-
overloaded heart initiated by mechanical stress. It is possible that syndecan-4 may act as a 
negative regulator of inflammation, which is in line with previous work35 also in the context 
of MI36 and heart failure.14  
We also demonstrated that collagen fiber formation was enhanced in vitro in the 
presence of ECsyn4, suggesting a novel role for syndecan-4 in facilitating collagen cross-
linking. Coincidentally, heparan sulfate GAG chains have been shown to interact with 
extracellular structural proteins such as collagen I37 and fibronectin.38 Other proteoglycans 
such as decorin and fibromodulin are known to bind to and stabilize collagen fibrils,39 and 
have been suggested40 to act as co-receptors for LOX. Indeed, collagen cross-linking by LOX 
appeared to be promoted in the presence of ECsyn4. Taken together, our results suggest a 
dual role for syndecan-4 in collagen cross-linking, inducing collagen and LOX expression by 
cardiac fibroblasts, and facilitating LOX cross-linking. In light of recent work reporting 
shedding of the extracellular domain of syndecan-4 in the failing human heart14 further 
studies are encouraged to determine the exact details of the syndecam-4-collagen interaction 
and its physiological significance. 
The limited number of therapeutic targets in cardiac fibrosis is a major problem for 
heart failure treatment. Syndecan-4 is upregulated in the pressure-overloaded left ventricle of 
mice14,5 and man,13 and based on recent research regarding the role of syndecan-4 in ECM 
remodeling we speculate that targeting syndecan-4 may be an effective anti-fibrotic 
approach.41,42 Supporting this, we here demonstrate for the first time that syndecan-4 
regulates passive tension in the pressure-overloaded myocardium by regulation of OPN and 
LOX expression, LOX activity and collagen cross-linking. Given that syndecan-4 is not only 
expressed in cardiac fibroblasts but also in cardiomyocytes, where it is necessary for the 
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development of concentric left ventricular hypertrophy in response to pressure overload,13 the 
next challenge will be to identify differential molecular traits between syndecan-4-dependent 
signaling in these two cell types (i.e. using cell specific knockouts of syndecan-4). This will 
allow to specifically target processes leading to changes in passive tension and to limit 
exacerbated fibrosis while maintaining intact the critical adaptive hypertrophic response of 
cardiomyocytes to pressure overload.
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Figure Legends
Figure 1. Myocardial passive tension is lower in mice lacking syndecan-4 due to altered 
ECM. Passive tension (A) and viscous stress (B) at 1.0- to 1.3-fold slack length (L0) of left 
ventricular muscle strips from wild-type (WT) and syndecan-4-/- (syn4-/-) mice 7 days after 
sham operation (sham) or aortic banding (AB). C, representative titin protein gel and 
summarized data showing left ventricular N2BA:N2B ratio. D, passive tension after salt 
extraction. E, electron microscope images of untreated (control) and salt extracted muscle 
strips. Scale bar 2μm. Two-way ANOVA analyses showed effect of genotype on passive 
tension before and after salt extraction. No difference in N2BA:N2B ratio (C) was found by 
using Kruskal-Wallis with Dunn's multiple comparison test. Data are presented as mean ± 
S.E.M. (A, B and D) for clearer visualization, and as mean ± S.D. (C). N=5-8. 
Figure 2. Increased syndecan-4 expression induces myofibroblast differentiation. A, 
LPPXQRIOXRUHVFHQFHVWDLQLQJRIVPRRWKPXVFOHĮ-actin (green) in cardiac fibroblasts from 
wild-type (WT) and syndecan-4-/- (syn4-/-) mice transduced with an empty adenoviral vector 
(adeno-null) or containing full-length syndecan-4 (adeno-syndecan-4). Scale bar 50μm. B, 
,PPXQRKLVWRFKHPLVWU\VKRZLQJVWDLQLQJIRUVPRRWKPXVFOHĮ-actin (SMA) and platelet-
GHULYHGJURZWKIDFWRUUHFHSWRUȕ3'*)5ȕLQOHIWYHQWULFXODUWLVVXH6FDOHEDUP
Relative mRNA levels of proliferating cell nuclear antigen (PCNA) normalized to GAPDH in 
left ventricles 24h (C) and 7 days (D) after AB, and cardiac fibroblasts plated on fibronectin 
for 48h and 72h (E). Statistical significance was determined by two-way ANOVA with 
Bonferroni post-hoc test (C-D) and Kruskal-Wallis with Dunn's multiple comparison test (E). 
n.s., not significant. Data are presented as mean ± S.D. N=8-10 (C-D); 4 (E).
Figure 3. Collagen cross-linking is reduced in the myocardium of syndecan-4-/- mice. A, 
total collagen determined by HPLC in left ventricles from wild-type (WT) and syndecan-4-/-
(syn4-/-) mice following sham operation (sham) or 7 days aortic banding (AB); B, cross-
linked collagen content in left ventricles from mice as in A; C, visualization of total collagen 
and cross-linked collagen using unpolarized and circularly polarized light, respectively, after 
picrosirius red staining of left ventricular sections from WT and syn4-/- mice; Scale bar 
100μm for total collagen and 50μm for cross-linked collagen. D and E, mRNA levels of 
collagen I and collagen III 7 days after AB. Statistical significance was determined by two-
way ANOVA with Bonferroni post-hoc tests (A, D and E) and Kruskal-Wallis with Dunn's 
multiple comparison test (B). Data are normalized to WT sham and presented as mean ± S.D. 
N=5-9 (A and B), 14-16 (D and E). 
Figure 4. Lysyl oxidase expression and activity is reduced in syndecan-4-/- mice. A, lysyl 
oxidase (LOX) mRNA levels in left ventricular tissue from wild-type (WT) and syndecan-4-/-
(syn4-/-) mice 24h after sham operation (sham) or aortic banding (AB). B, LOX mRNA in 
cardiac fibroblasts from WT and syn4-/- mice plated on fibronectin for 72h to induce 
myofibroblast differentiation. C, LOX activity in left ventricular tissue from WT and syn4-/-
mice subjected to sham operation or 3 days AB. Two-way ANOVA with Bonferroni post-hoc 
test (A), Mann-Whitney test (B) and Kruskal-Wallis with Dunn's multiple comparison test 
(C) were applied. Data are relative to WT sham (A and C) or WT (B) and presented as mean 
± S.D. N=10 (A), 5 (B), 7-8 (C).  
Figure 5. Osteopontin is regulated by syndecan-4. Osteopontin (OPN) mRNA (A and C) 
and protein (B) in left ventricular tissue from wild-type (WT) and syndecan-4-/- (syn4-/-) mice 
24h (A and B) and 7 days (C) after sham operation (sham) or aortic banding (AB). D, 
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correlation of cardiac lysyl oxidase (LOX) and OPN mRNA 3 and 7 days after sham or AB 
determined by Pearson regression analysis. E, OPN mRNA levels in cardiac fibroblasts from 
WT and syn4-/- mice 6, 24, 48 and 72h after plating on fibronectin. HT1080 fibroblasts 
control (ctrl) and overexpressing syndecan-4 (syn4) and calcineurin (CaN; F) and H, 
NFATc4. G, cardiac fibroblasts treated with an NFAT blocker. Significant differences were 
determined by two-way ANOVA with Bonferroni post-hoc test (A-C, E), Mann-Whitney test 
(F and H) and Student’s paired t-test (G). Data are relative to WT sham (A-D), WT 6h (E) 
and ctrl (F-H) and presented as mean ± S.D. N=8-10 (A-C), 5-6 (E-H)
Figure 6. Syndecan-4 facilitates collagen cross-linking by LOX. A and C, turbidity 
measured as optical density at 340nm of solutions containing collagen, extracellular 
syndecan-4 (ECsyn4) and lysyl oxidase (LOX). B and D, electron microscopy images of 
collagen alone or mixed with ECsyn4 with and without LOX, or ECsyn4 alone. Asterisks 
denote structures only present in solutions containing both collagen and ECsyn4 (B) or 
collagen and LOX (D). Arrows indicate inter-fibrillar structures (D). Scale bars: 1μm (upper 
panel in B, and in D) and 200nm (lower panel in B). Comparisons are made by Mann-
Whitney to the ctrl in A and C and significance denoted with * or n.s. for non significant 
comparisons. Data are relative to collagen (A) and collagen with LOX (B) and presented as 
mean ± S.D. N=3-6. 
Figure 7. Syndecan-4 regulates cardiac fibroblast phenotype and function, collagen 
cross-linking and myocardial stiffness in response to mechanical stress. Schematic model 
showing syndecan-4 expression (green) during the sequence of events taking place in 
response to left ventricular pressure overload in mice. Syndecan-4 expression is based on 
previously published data14 for 0, 24h, 7 and 21 days; as well as data for 0 and 3 days in this 
study. AB, aortic banding; mech. stress, mechanical stress; syn4, syndecan-4; CaN, 
calcineurin.







Supplementary Material
Detailed Methods
Mouse Model of Pressure Overload 
AB of the ascending aorta or sham operations were performed on 8-12 week old male 
C57Bl/6JBomTac wild-type (WT) and syndecan-4 knockout (syndecan-4-/-) mice1 on 
C57BL/6J background (000664, The Jackson Laboratory, Bar Harbor, ME) as previously 
described.2 Mice were initially anesthetized with 5% isoflurane and 95% oxygen in a chamber. 
Subsequently, mice were intubated and ventilated with 3% isoflurane and 97% oxygen. For 
post-operative analgesia, animals were given 0.02 ml buprenorphine (0.3 mg/ml) 
subcutaneously and allowed to recover at 35ºC. Animals with an aortic flow velocity > 4 m/s, 
as determined by echocardiography were included in the study. Before euthanizing the mice 
by cervical dislocation 24h, 3 days or 7 days after AB, echocardiography was performed as 
previously described.2,3
Mechanical measurements
Muscle strips from snap frozen left ventricular tissue were skinned in 0.5% Triton X-100 in 
relaxing solution containing (in mM): ATP 7.8; creatine phosphate 20; imidazole 20; EGTA 
4; Mg-propionate 12; K-propionate 97.6 (pH 7.1), and passive force was measured at room 
temperature after mounting the strips between two stainless steel clips attached to a 
micromotor and a force transducer (Scientific Instruments, Heidelberg, Germany). L0 was set 
by determining slack length, verified in three muscle strips by laser diffraction.4,5 to 
correspond to a sarcomere length of 1.8 μm. Muscle strips were stretched in several equal 
steps, each followed by a 1-minute hold period,to a maximum of 30 % L0, corresponding to a 
sarcomere length of ~2.3 μm. Quasi steady-state passive force at the end of the hold period 
was determined as a measure of the elastic component of the muscle strip, and was related to
the cross-sectional area at the thinnest point of the strip at slack length, to obtain passive 
tension. Viscous stress, reflecting the stretch velocity sensitive component of the muscle, was 
determined as peak force upon stretching minus steady-state force, divided by cross-sectional 
area. Salt extraction of actin and myosin filaments was performed by treatment with 0.6 M 
KCl (Sigma, Schnelldorf, Germany) for 20 min, followed by 1 M KI (Sigma) for 20 min.6
After passive tension measurements, muscle strips were fixed and disruption of sarcomere 
structure verified by electron microscopy. Mean passive tension/viscous stress values were 
plotted against L0 and best fits to mean data points were made using exponential growth 
equations.  
Collagen cross-linking and quantification 
For visualization of cross-linked collagen, left ventricles were fixed in 4 % neutral buffered 
formalin, dehydrated, cleared and embedded in paraffin. Transverse sections (4 μm) were 
stained with picrosirius red and examined by light microscopy with polarized light. For 
collagen quantification, thick transverse sections (20 μm) were stained with picrosirius red 
(Sigma) and normalized to total protein content determined by fast green (Sigma) staining.7
The amount of soluble collagen was assessed using colorimetric and enzymatic procedures as 
previously described7,8 and by using Sircol Collagen Assay from Biocolor (Carrickfergus, 
UK). 
Fibroblast Cell Culture
Neonatal mice were sacrificed by decapitation and cardiac fibroblasts isolated as previously 
described9 and used at passage 2 to limit in vitro effects on fibroblast phenotype. Cells were 
seeded on fibronectin-coated plates to induce myofibroblast differentiation, as previously 
shown to mimic the phenotypic modulation that takes place in vivo during pressure overload 
of the left ventricle.9 LOX expression was measured in cardiac fibroblasts from neonatal WT 
and syndecan-4-/- after 24, 48 and 72h on fibronectin. Also, cardiac fibroblasts from 6-12 
week old mice (sacrificed by decapitation after anesthesia with isoflurane in a chamber) were 
isolated using collagenase2 and transduced with adenoviral vector containing mouse 
syndecan-4 (196608A; Applied Biological Materials Inc, Richmond, Canada). Cardiac 
fibroblasts were stimulated with 10 QJPO7*)ȕGF111, Merck Millipore, Darmstadt, 
Germany) and 250 ng/ml OPN (Cat. no.120-35; Peprotech, Hamburg, Germany). Human 
fibrosarcoma HT1080 fibroblasts were transfected with mouse syndecan-4 (NP_035651.1; 
HA-tagged), mouse calcineurin (A000420; His-tagged) NFATc3 (NP 035031; GFP-tagged) 
or NFATc4 (NP_076188; GFP-tagged) custom made by Genscript (Piscataway, NJ) using 
lipofectamine 2000 (Invitrogen, Paisley, UK) according to the manufacturer’s protocol. 
Successful transfection was determined by real-time PCR on syndecan-4 (Mm00488527_m1), 
calcineurin (Mm01317678_m1) and NFATc4 (Mm00452373_g1). Cells were cultured in 
Dulbecco’s Modified Eagles Medium (41965 GIBCO-BRL, Invitrogen, Paisley, UK) 
supplemented with 10% fetal calf serum (14-701E, Bio-Whittaker, Lonza, Basel, Switzerland) 
and penicillin/streptomycin (G6784, Sigma, St. Louis, MO). The NFAT blocker A-285222 
was kindly provided by Abbott Laboratories (1μmol/L; Abbott Park, IL).  
Gene Expression Analysis  
RNA was extracted from frozen left ventricles and cell cultures using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany). Only samples with RNA integrity number (RIN) > 6, assessed 
using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) were accepted. cDNA 
synthesis was performed using the iScript cDNA Synthesis Kit (BIO-RAD, Hercules, CA). 
Quantitative real-time PCR with predesigned TaqMan assays (Applied Biosystems, Foster 
City, CA) was used to assess the expression of proliferating cell nuclear antigen (PCNA; 
Mm00448100_m1) collagen I (Mm00483888_m1) and collagen III (Mm00802331_m1), 
OPN (Mm00436767_m1, Hs00959010_m1), LOX (Mm00495386_m1) and glyceraldehydes 
3-phosphate dehydrogenase (GAPDH; Mm03302249_g1, Hs99999905_m1), MMP2 
(Mm00439506_m1), MMP9 (Mm00442991_m1), MMP13 (Mm00439491_m1), TIMP1 
(Mm00441818_m1), TIMP2 (Mm00441825_m1), fibronectin (Mm01256744_m1), elastin 
(Mm00514670_m1), CD44 (Mm01277163_m1), Itgav (Mm00434486_m1) and Itgb1
(Mm01253230_m1). Data were normalized to GAPDH.
Immunoblotting 
Immunoblotting was performed on left ventricle homogenates as previously described.10 Anti-
osteopontin (IBL, Hamburg, Germany) and anti-LOX (NB100-2527, Novus Biologicals, 
Littleton, CO) were used as primary antibodies. 
Immunocytochemistry 
Cells grown on fibronectin-coated glass cover slips were fixed in 4% paraformaldehyde
(Sigma) and stained using mouse-anti-SMA (1:300, Sigma) and alexa fluor 488- secondary 
anti-mouse antibodies (Invitrogen). Images were obtained a LSM 710 confocal microscope 
(Zeiss). Nuclei were stained with sytox orange (Invitrogen). Staining with IgG2a or omitting 
primary antibodies served as negative controls.  
Immunohistochemistry 
Formalin-fixed myocardial tissue sections (4 μm) were stained for SMA (1:250, M0851, 
DAKO, Glostrup, Denmark) and platelet-derived growth factor receptor ȕ3'*)5ȕ
#4564, Cell Signaling, Danvers, MA) and visualized by the use of secondary antibodies 
conjugated to horseradish peroxidase (HRP). Positive controls were obtained by staining 
tissue from appendix and lung cancer for SMA and PDGFR, respectively. 
In vitro collagen fiber formation assay 
A recombinant protein (1-4 μg) consisting of the extracellular domain of syndecan-4 fused 
with the Fc region of human IgG1 (syndecan-4 homodimer; Sino Biological Inc., Beijing, 
China) was mixed with 10 μg collagen I (BD Biosciences, Bedford, MA) in 25 μl TES buffer, 
2 μL 10 mM ZnSO4 and distilled water to a total volume of 50 μl, with or without 
recombinant human lysyl oxidase homolog 2 (0,1μg, LOXL2 with activity > 2 pmol/min/μg, 
R&D systems, Abingdon, UK). The mixture was incubated at 37 ºC for 24-72 h. After mixing 
vigorously, turbidity of the solution was measured as optical density at 340 nm and content 
examined with electron microscopy by performing negative staining with 2% aqueous uranyl 
acetate directly on the grids. 
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Supplementary Table 1. Mice lacking syndecan-4 have reduced left ventricular 
concentric hypertrophy after 7 days of pressure overload. Echocardiography revealed 
significant differences between wild-type (WT) and syndecan-4-/- (syn4-/-) mice subjected to 
aortic banding (AB) as indicated with * and significant difference between sham operated 
animals (sham) and those subjected to 7 days AB as denoted with # as determined by two-way 
ANOVA with Bonferroni post-hoc test. LV, left ventricular; LAD, left atrial diameter; IVSd, 
end diastolic interventricular septum thickness; LVPWd, end diastolic left ventricular 
posterior wall thickness; LVIDd, end diastolic left ventricular internal diameter; LVFS, left 
ventricular fractional shortening; E, early mitral inflow velocity; E´, early mitral annular 
velocity. Data are presented as mean ± S.D.
Sham AB 
WT syn4-/- WT syn4-/-
N 14-16 14-15 15-16 13-17
Body weight, g 26.41 ± 1.72 25.30 ± 2.45 25.83 ± 1.52 23.70 ± 2.38*
Tibia length (TL), mm 17.69 ± 0.62 17.17 ± 0.47 17.54 ± 0.53 17.52 ± 0.30
LV weight/TL, mg/mm 4.99 ± 0.26 5.07 ± 0.69 8.28 ± 0.73### 8.15 ± 1.04###
Lung weight/TL, mg/mm 8.51 ± 0.81 8.58 ± 0.92 17.47 ± 4.99### 14.82 ± 3.52###
LAD, mm 1.80 ± 0.10 1.76 ± 0.13 3.14 ± 0.35### 3.16 ± 0.36###
IVSd, mm 0.53 ± 0.06 0.53 ± 0.08 1.03 ± 0.18### 0.81 ± 0.17***###
LVPWd, mm 0.52 ± 0.08 0.58 ± 0.09 1.15 ± 0.19### 0.90 ± 0.12***###
LVIDd, mm 4.33 ± 0.29 4.18 ± 0.34 3.91 ± 0.40## 4.24 ± 0.38*
LVFS, % 19.46 ± 3.51 17.03 ± 4.28 11.59 ± 4.67### 11.29 ± 3.66###
E/E´ 37.58 ± 9.65 34.34 ± 5.90 50.48 ± 12.54## 47.82 ± 11.92##
(IVSd + LVPWd) / LVID 0.25 ± 0.04 0.27 ± 0.04 0.57 ± 0.12### 0.41 ± 0.06***###
LV weight/LVID (mg/mm) 20.71 ± 1.32 20.39 ± 1.95 37.33 ± 3.72### 33.90 ± 5.11*###
Supplementary Table 2. Non-cardiomyocyte, blood vessel and fibroblast fraction in left 
ventricular tissue. Quantitative analysis of electron micrographs of left ventricular tissue 
sections. Comparisons between sham operated (sham) and aortic banded (AB) animals were 
made using Mann-Whitney test as indicated with #. No significant differences were found 
between wild-type (WT) and syndecan-4-/- (syn4-/-) mice. Non-CM, non-cardiomyocyte; WT, 
wild-type; syn4-/-, syndecan-4-/-; sham. Data are presented as mean ± S.D. N=6-10 tissue 
sections.
Sham 7 days after AB 
WT syn4-/- WT syn4-/-
N 6 10 6 8
Non-CM fraction, % 29.6 ± 4.0 31.5 ± 8.2 26.3 ± 6.1 24.6 ± 0.9
Area occupied by fibroblast nuclei in 
non-CM fraction, % 
2.52 ± 0.8 2.65 ± 2.5 6.73 ± 2.1## 5.28 ± 2.2#
Area occupied by blood vessels in 
non-CM fraction, %
46.2 ± 15.2 29.1 ± 8.8 35.8 ± 11.4 35.7 ± 7.4 
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